U.S. patent application number 17/383104 was filed with the patent office on 2022-02-03 for stimulation of an immune response by cationic lipids.
The applicant listed for this patent is PDS Biotechnology Corporation. Invention is credited to Frank Bedu-Addo, Weihsu Chen, Gregory Conn, Leaf Huang, Kenya Johnson, Weili Yan.
Application Number | 20220031650 17/383104 |
Document ID | / |
Family ID | 1000005902304 |
Filed Date | 2022-02-03 |
United States Patent
Application |
20220031650 |
Kind Code |
A1 |
Chen; Weihsu ; et
al. |
February 3, 2022 |
STIMULATION OF AN IMMUNE RESPONSE BY CATIONIC LIPIDS
Abstract
The present invention provides compositions and methods for
stimulating an immune response using cationic lipids alone or in
combination with antigens.
Inventors: |
Chen; Weihsu; (Toronto,
CA) ; Yan; Weili; (Auburn, AL) ; Johnson;
Kenya; (Mason, OH) ; Conn; Gregory; (Madrid,
ES) ; Bedu-Addo; Frank; (Bethel, CT) ; Huang;
Leaf; (Durham, NC) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
PDS Biotechnology Corporation |
North Brunswick |
NJ |
US |
|
|
Family ID: |
1000005902304 |
Appl. No.: |
17/383104 |
Filed: |
July 22, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14531469 |
Nov 3, 2014 |
|
|
|
17383104 |
|
|
|
|
12049957 |
Mar 17, 2008 |
8877206 |
|
|
14531469 |
|
|
|
|
60896412 |
Mar 22, 2007 |
|
|
|
60911549 |
Apr 13, 2007 |
|
|
|
60948512 |
Jul 9, 2007 |
|
|
|
60983799 |
Oct 30, 2007 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 45/06 20130101;
A61K 31/14 20130101; C07C 219/06 20130101; A61K 47/646 20170801;
A61K 39/39 20130101; A61K 31/231 20130101; A61K 39/0011 20130101;
A61K 2039/55555 20130101; A61K 39/12 20130101; A61K 39/00 20130101;
A61K 31/20 20130101 |
International
Class: |
A61K 31/231 20060101
A61K031/231; A61K 31/20 20060101 A61K031/20; A61K 39/00 20060101
A61K039/00; A61K 39/39 20060101 A61K039/39; A61K 47/64 20060101
A61K047/64; A61K 31/14 20060101 A61K031/14; A61K 39/12 20060101
A61K039/12; A61K 45/06 20060101 A61K045/06; C07C 219/06 20060101
C07C219/06 |
Claims
1. A method of treating a coronavirus infection in a mammal, the
method comprising administering at least one cationic lipid
together with at least one coronavirus-associated antigen, wherein
the cationic lipid is administered to the mammal in an amount
sufficient to activate the MAP kinase signaling pathway to elicit
an immunostimulatory adjuvant effect, wherein a mouse dose of
cationic lipid is between 10 nmol and about 400 nmol, and wherein
the mammal dose of cationic lipid is determined from the mouse
dose.
2. The method of claim 1 wherein the cationic lipid is a
nonsteroidal cationic lipid comprising at least one fatty acid or
alkyl chain.
3. The method of claim 1 wherein the cationic lipid is selected
from the group consisting of DOTAP, DOTMA, DOEPC, and combinations
thereof.
4. The method of claim 1 wherein the cationic lipid is DOTAP.
5. The method of claim 1 wherein the immunostimulatory adjuvant
effect results in the attenuation or curing of the coronavirus
infection.
6. The method of claim 1 wherein the antigen is modified to
increase its hydrophobicity, wherein the antigen is modified via
conjugation to a lipid chain or via conjugation to one or more
hydrophobic amino acids.
7. The method of claim 6 wherein the coronavirus-associated antigen
is a lipidated antigen.
8. The method of claim 7 wherein the coronavirus-associated antigen
is lipidated with palmitic acid.
9. The method of claim 8 wherein the palmitic acid is linked to the
coronavirus-associated antigen via a spacer, wherein the spacer is
an amino acid sequence of K-S-S.
10. A method of reducing the regulatory T-cell population in a
mammal in need thereof, the method comprising administering to the
mammal at least one cationic lipid and at least one
coronavirus-associated antigen, wherein a mouse dose of cationic
lipid is between 10 nmol and about 400 nmol, and wherein the mammal
dose of cationic lipid is determined from the mouse dose.
11. The method of claim 10 wherein the cationic lipid is a
nonsteroidal cationic lipid comprising at least one fatty acid or
alkyl chain.
12. The method of claim 10 wherein the cationic lipid is selected
from the group consisting of DOTAP, DOTMA, DOEPC, and combinations
thereof.
13. The method of claim 10 wherein the cationic lipid is DOTAP.
14. A method of using a cationic lipid to elicit an
immunostimulatory adjuvant effect in an immune system of a mammal,
wherein the cationic lipid is administered with at least one
coronavirus-associated antigen to the mammal in an amount
sufficient to activate the MAP kinase signaling pathway to elicit
the immunostimulatory adjuvant effect, wherein a mouse dose of
cationic lipid is between 10 nmol and about 400 nmol, and wherein
the mammal dose of cationic lipid is determined from the mouse
dose.
15. The method of claim 14 wherein the cationic lipid is a
nonsteroidal cationic lipid comprising at least one fatty acid or
alkyl chain.
16. The method of claim 14 wherein the cationic lipid is selected
from the group consisting of DOTAP, DOTMA, DOEPC, and combinations
thereof.
17. The method of claim 14 wherein the cationic lipid is DOTAP.
18. The method of claim 1 wherein the amount of cationic lipid is
between about 30 nmol and about 300 nmol.
19. The method of claim 10 wherein the amount of cationic lipid is
between about 30 nmol and about 300 nmol.
20. The method of claim 14 wherein the amount of cationic lipid is
between about 30 nmol and about 300 nmol.
21. A method of inducing an antibody response against an
coronavirus-associated antigen in a mammal, the method comprising
administering at least one cationic lipid together with at least
one coronavirus-associated antigen, wherein the cationic lipid is
administered to the mammal in an amount sufficient to induce the
antibody response in response against the antigen, wherein a mouse
dose of cationic lipid is between 10 nmol and about 400 nmol, and
wherein the mammal dose of cationic lipid is determined from the
mouse dose.
22. The method of claim 21 wherein the cationic lipid is a
nonsteroidal cationic lipid comprising at least one fatty acid or
alkyl chain.
23. The method of claim 21 wherein the cationic lipid is selected
from the group consisting of DOTAP, DOTMA, DOEPC, and combinations
thereof.
24. The method of claim 21 wherein the cationic lipid is DOTAP.
25. The method of claim 21 wherein the coronavirus-associated
antigen is modified to increase its hydrophobicity, wherein the
antigen is modified via conjugation to a lipid chain or via
conjugation to one or more hydrophobic amino acids.
26. The method of claim 25 wherein the coronavirus-associated
antigen is a lipidated antigen, and wherein the lipidated antigen
is lipidated with palmitic acid.
27. The method of claim 26 wherein the palmitic acid is linked to
the antigen via a spacer, wherein the spacer is an amino acid
sequence of K-S-S.
28. The method of claim 21 wherein the amount of cationic lipid is
between about 30 nmol and about 300 nmol.
29. The method of claim 1, wherein the mammal is a human.
30. The method of claim 1, wherein the mammal is a non-human.
31. The method of claim 1, wherein the mouse dose of cationic lipid
is between 0.05 nmol per microliter (.mu.L) to about 3 nmol per
.mu.L.
32. The method of claim 1, wherein the mouse dose of cationic lipid
is between 0.05 mg per milliliter (mL) to about 2 mg per mL.
33. The method of claim 10, wherein the mammal is a human.
34. The method of claim 10, wherein the mammal is a non-human.
35. The method of claim 10, wherein the mouse dose of cationic
lipid is between 0.05 nmol per microliter (.mu.L) to about 3 nmol
per .mu.L.
36. The method of claim 10, wherein the mouse dose of cationic
lipid is between 0.05 mg per milliliter (mL) to about 2 mg per
mL.
37. The method of claim 14, wherein the mammal is a human.
38. The method of claim 14, wherein the mammal is a non-human.
39. The method of claim 14, wherein the mouse dose of cationic
lipid is between 0.05 nmol per microliter (.mu.L) to about 3 nmol
per .mu.L.
40. The method of claim 14, wherein the mouse dose of cationic
lipid is between 0.05 mg per milliliter (mL) to about 2 mg per
mL.
41. The method of claim 21, wherein the mammal is a human.
42. The method of claim 21, wherein the mammal is a non-human.
43. The method of claim 21, wherein the mouse dose of cationic
lipid is between 0.05 nmol per microliter (.mu.L) to about 3 nmol
per .mu.L.
44. The method of claim 21, wherein the mouse dose of cationic
lipid is between 0.05 mg per milliliter (mL) to about 2 mg per mL.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The application is a continuation of U.S. patent application
Ser. No. 14/531,469, which was filed Nov. 3, 2014, which is a
continuation of U.S. patent application Ser. No. 12/049,957, which
was filed Mar. 17, 2008, which claims benefit of U.S. Provisional
Application Nos. 60/896,412, filed Mar. 22, 2007, by Weishu Chen
and Leaf Huang, and entitled "Cationic-Lipid Based Immune Stimulant
for Treatment of Disease"; 60/911,549, filed Apr. 13, 2007, by Leaf
Huang and Weishu Chen, and entitled "Cationic-Lipid Based Dual
Function Delivery System and Immune Stimulant for Treatment of
Disease"; 60/948,512, filed Jul. 9, 2007, by Leaf Huang, Weishu
Chen, and Weili Yan, and entitled "Cationic-Lipid Based Dual
Function Delivery System and Immune Stimulant for Treatment of
Disease"; and 60/983,799, filed Oct. 30, 2007, by Weishu Chen and
Leaf Huang, and entitled "Induction of Immune Responses by a
Liposomal Peptide Formulation," the disclosures of which are
incorporated by reference herein in their entireties.
FIELD OF THE INVENTION
[0002] The present invention generally relates to stimulating an
immune response, and more particularly to the role of lipids in
immune responses.
SEQUENCE LISTING
[0003] The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on September 17, 2021, is named PDS-16-1016CON-CON1 SL.txt and is
2,595 bytes in size.
BACKGROUND OF THE INVENTION
[0004] This section is intended to introduce the reader to various
aspects of art that may be related to various aspects of the
present invention, which are described and/or claimed below. This
discussion is believed to be helpful in providing the reader with
background information to facilitate a better understanding of
various aspects of the present invention. Accordingly, it should be
understood that these statements are to be read in this light, and
not as admissions of prior art.
[0005] Development of safe and effective immunotherapies for human
use remains an urgent medical need for patients worldwide. In order
to elicit appropriate immune responses, immunologic modifiers
("immunomodifiers") that enhance, direct, or promote an immune
response can be used in vaccine design or immunotherapy
[Gregoriadis, G., Immunological adjuvants: a role for liposomes.
Immunol Today 11:89 (1990)]. For example, vaccines may include
antigens to stimulate an immune response. However, some potential
vaccines that include antigens are weak stimulators of an immune
response because the vaccines do not efficiently deliver the
antigen to antigen presenting cells ("APC") of the immune system
and/or the antigen is weakly immunogenic. Thus, immunotherapies
that effectively deliver antigens to APC, and also stimulate the
immune system to respond to the antigen, are needed.
Immunomodifiers have the potential to function as such an
immunotherapy. Such immunotherapies may have these and other
benefits. For example, when included as part of a therapeutic
vaccine, an immunomodifier should at least (1) improve antigen
delivery and/or processing in the APC [Wang, R. F., and Wang, H. Y.
Enhancement of antitumor immunity by prolonging antigen
presentation on dendritic cells. Nat Biotechnol 20:149 (2002)], (2)
induce the production of immunomodulatory cytokines that favor the
development of immune responses to the vaccine antigen, thus
promoting cell mediated immunity, including cytotoxic T-lymphocytes
("CTL"), (3) reduce the number of immunizations or the amount of
antigen required for an effective vaccine [Vogel, F. R. Improving
vaccine performance with adjuvants. Clin Infect Dis 30 Suppl 3:S266
(2000)], (4) increase the biological or immunological half-life of
the vaccine antigen, and (5) overcome immune tolerance to antigen
by inhibiting immune suppressive factors [Baecher-Allan, C., and
Anderson, D. E. Immune regulation in tumor-bearing hosts. Curr Opin
Immunol 18:214 (2006)].
[0006] Presently, the primary class of agents used to enhance the
efficacy of antigens, such as peptide or protein antigens, in
eliciting an immune response are adjuvants such as water-in-oil
emulsions, alum, and other chemicals which enhance antigen
responses; however, these adjuvants are not immunomodifiers, as
described above, because they have no direct immunomodulatory
effects themselves [Vogel, F. R., and Powell, M. F. A compendium of
vaccine adjuvants and excipients, Pharm Biotechnol 6:141 (1995)].
Several such adjuvants are available for use in animals and some of
them have been tested in clinical trials. In addition to
traditional adjuvants such as the aluminum salts, products such as
influenza virosomes [Gluck, R., and Walti, E. 2000. Biophysical
validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with
immunopotentiating reconstituted influenza virosomes (IRIV). Dev
Biol (Basel) 103:189 (2000)] and Chiron's MF59 [Kahn, J. O., et al.
Clinical and immunologic responses to human immunodeficiency virus
(HIV) type 1SF2 gp 120 subunit vaccine combined with MF59 adjuvant
with or without muramyl tripeptide dipalmitoyl
phosphatidylethanolamine in non-HIV-infected human volunteers. J
Infect Dis 170:1288 (1994)], which have intrinsic immune effects,
are being marketed. For example, MF59, which is a submicron
emulsion based adjuvant, is internalized by dendritic cells
[Dupuis, M., et al., Dendritic cells internalize vaccine adjuvant
after intramuscular injection. Cell Immunol 186:18 (1998)].
However, according to clinical trial reports on HSV and influenza
vaccines [Jones, C. A., and Cunningham, A. L. Vaccination
strategies to prevent genital herpes and neonatal herpes simplex
virus (HSV) disease. Herpes 11:12 (2004); Minutello, M. et al.,
Safety and immunogenicity of an inactivated subunit influenza virus
vaccine combined with MF59 adjuvant emulsion in elderly subjects,
immunized for three consecutive influenza seasons. Vaccine 17:99
(1999)], evidence from animal models suggests that the MF59
adjuvant enhances production of neutralizing antibodies rather than
enhancing T-cell responses. Thus new methods of stimulating cell
mediated immune responses are needed.
[0007] Further, as mentioned above, some antigens are weak
stimulators of an immune response. Thus, in addition to
co-administering antigen with substances that stimulate immune
responses, as described above, a weakly immunogenic antigen can be
modified to increase its immunogenicity. For example, a weakly
immunogenic antigen can be coupled to immunogenic peptides,
polysaccharides, or lipids to increase its immunogenicity. However,
simply coupling weakly immunogenic antigens to these types of
compounds may not be sufficient to elicit an immune response. For
example, the resulting immune response may be directed to
immunogenic epitopes on the coupled compound and not the weak
antigen, or the coupled antigen may not be efficiently delivered
APC of the immune system. Thus, additional methods are needed to
stimulate immune responses to antigens that are weakly
immunogenic.
SUMMARY OF THE INVENTION
[0008] Certain exemplary aspects of the invention are set forth
below. It should be understood that these aspects are presented
merely to provide the reader with a brief summary of certain forms
the invention might take and that these aspects are not intended to
limit the scope of the invention. Indeed, the invention may
encompass a variety of aspects that may not be explicitly set forth
below.
[0009] This invention is directed to the use of cationic lipids,
which under certain dose and composition conditions act as a novel
class of immune-stimulants, to (1) effectively present or deliver
an antigen to the immune system and (2) stimulate the immune system
to respond to the antigen.
[0010] Liposomes have been extensively used for delivering small
molecular weight drugs, plasmid DNA, oligonucleotides, proteins,
and peptides. Vaccines using liposomal vehicles as non-viral
antigen carriers are preferable compared to traditional
immunizations using live attenuated vaccines or viral vectors such
as vaccinia or influenza virus. U.S. Pat. No. 7,303,881, describes
a simple yet effective lipid-based immunotherapy, a cationic
lipid/antigen complex, which consists of two molecules, the
cationic lipid and an antigen, and to which additional components
such as stabilizers, adjuvants and surface modifiers could be added
[See U.S. Pat. No. 7,303,881]. The formulation, which consists of a
cationic lipid, and an antigen [e.g., E7, a human papilloma virus
("HPV")], induces both preventative and therapeutic anti-tumor
immune responses against HPV-positive TC-1 tumor in a mouse model.
The results demonstrate that the cationic liposome complexed with
an antigen serves to stimulate immune responses and initiate
dendritic cell (an APC) interaction with T-cells.
[0011] In the present invention, additional studies performed to
further understand the ability of the cationic lipid/antigen
complex to induce a potent immune response, have led to the
discovery that the cationic lipids on their own can act as potent
immune activators under low dose conditions by activating
components of the mitogen-activated protein ("MAP") kinase
signaling pathway, which exists in all mammalian species. In
combination with an antigen, the cationic lipid/antigen complex,
under low dose conditions, induces strong immune responses specific
to the antigen formulated in the complex. At higher cationic lipid
doses, reactive oxygen species (ROS) are produced in excess in the
immune cells and dampens the observed immune response.
[0012] Thus, one aspect of the invention provides a composition of
at least one cationic lipid in a dose sufficient to induce an
immune response in a subject by activating MAP kinase signaling by
the cells of the immune system of a subject.
[0013] Another aspect of the invention provides a method of
inducing an immune response in a subject by activating the MAP
kinase signaling pathway by administering a cationic lipid to the
subject.
[0014] Another aspect of the invention provides a composition of at
least one cationic lipid in a dose sufficient to induce an immune
response by inducing the production of reactive oxygen species
("ROS") in the cells of the immune system of the subject. The
cationic lipid complex stimulates ROS production to levels
sufficient to increase the immune response above the immune
response present in the absence of the at least one cationic
lipid.
[0015] Another aspect of the invention provides a method of
inducing immune response by administering to a subject a cationic
lipid complex to induce the production of reactive oxygen species
("ROS") in the cells of the immune system of the subject. The
cationic lipid complex stimulates ROS production to levels
sufficient to increase the immune response above the immune
response present in the absence of the at least one cationic lipid.
Additional aspects of the invention involve the addition of at
least one antigen to form a cationic lipid/antigen complex in which
case the immune response is antigen-specific.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Various features, aspects, and advantages of the present
invention will become better understood when the following detailed
description is read with reference to the accompanying figures in
which like characters represent like parts throughout the figures,
wherein:
[0017] FIG. 1 is a graph depicting in vitro cytokine production
after stimulation of dendritic cells
with1,2-dioleoyl-3-trimethylammonium propane ("DOTAP").
[0018] FIG. 2 Analysis of CTL-mediated cytotoxicity by flow
cytometry. E7-specific cytotoxic T-lymphocyte ("CTL") clones were
prepared and expanded. After five days in vitro restimulation with
E7 peptide, effector cells were incubated with PKH-67 labeled TC-1
target cells at the indicated effector:target ratio for 4 h at
37.degree. C. BL-6 was used as a non-specific target cell control.
Percentage of E7-specific killing was determined by the percentage
of PI positive cells within the gating of PKH-67 positive target
cells in flow cytometry. Statistical analysis was calculated by
comparing with control group at 100:1 E:T ratio (*p<0.01,
**p<0.001, n=5).
[0019] FIG. 3 Tumor infiltrating T-lymphocytes were observed in
mice that received DOTAP/E7 at the optimal lipid dose. TC-1 tumors
were established as described and were left untreated or treated
with a single injection on day 6. Solid tumors were dissected on
day 14 and examined for infiltrating lymphocytes. FITC conjugated
anti-CD8 (A, B, C) and anti-CD4 (D, E, F) antibodies were used to
determine tumor infiltrating T cells followed by counterstaining
with DAPI. Representative tumor sections from groups of 3 mice were
examined as described and imaged with confocal microscopy. TUNEL
assay was conducted to detect apoptosis in the tumor sections (G,
H, I).
[0020] FIG. 4 is a graph depicting induction of humoral activity by
treatment with cationic lipid treatment.
[0021] FIG. 5 is a graph illustrating the reduction in the T
regulatory cell population in mice after receiving DOTAP with E7
peptide using flow cytometry.
[0022] FIG. 6 Kinetics of TC-1 tumor growth in mice treated with
DOTAP/E7 formulations. On day 6 post TC-1 inoculation, mice
received treatment of 10 .mu.g E7 peptide formulated in DOTAP
liposomes at various lipid concentrations. TC-1 tumor size of each
group at day 23 was compared to the untreated control group and was
analyzed statistically (*p<0.05, **p<0.01,
***p<0.001).
[0023] FIG. 7 Subcutaneous injection of DOTAP induces dendritic
cell activation and migration to the draining lymph node. Naive
mice (n=4-6) were injected with PBS control (A, C and E) or
DOTAP/E7 containing 100 nmols total lipid with 0.5% NBD-DOTAP (B, D
and F). At 4 h after the injection, draining lymph node cells were
prepared and stained with appropriate antibodies to surface
markers. The co-expression of NBD and CD1 lc (A and B) or CD86 (C
and D) were analyzed within total lymph node cells whereas the
co-expression of NBD and CD8 (E and F) were gated and analyzed
within CD3+ population. The numbers represent the percentages of
cells in the quadrants.
[0024] FIG. 8 shows that immunization with E7 peptide formulated in
optimal DOTAP adjuvant elicits functional CD8.sup.+ T cells. The
numbers of CD8.sup.+ IFN-.gamma..sup.+cells per 10.sup.5 CD8.sup.+
T cells were shown as mean.+-.SD and were compared to the untreated
control (n=4, **p<0.01).
[0025] FIG. 9 is a Plot illustrating the anti-tumor immune response
of cationic lipid/E7 complexes composed of various cationic lipids
compared to potent adjuvants known to elicit a T-cell response
[0026] FIGS. 10A-C are graphs illustrating ROS production in the
draining lymph node of mice and correlated with the anti-tumor
immune response. FIG. 10A Draining lymph nodes ("DLN") from mice
that received injections of DOTAP/E7 containing 0, 15, 100 or 600
nmol lipid were isolated 2 h after the injection. The relative
percentages of cells with positive ROS signals are listed. FIG. 10B
Cytotoxicity in the DLN was measured by collecting cells at 10 h
after DOTAP/E7 injection by flow cytometry. The relative
percentages of dead cells (PI positive) in DC (open square) and the
numbers of live DC per 10.sup.5 LN cells (bars) were shown and
compared with that of the untreated control by paired Student's t
test (**P<0.01). FIG. IOC Reactive oxygen species ("ROS")
production in DLN was diminished by co-formulation of an inert
neutral lipid, dioleoyl phosphatidylcholine ("DOPC") with DOTAP/E7
(mole ratio of DOPC/DOTAP=5), resulting in decreased anti-tumor
activity of the complex.
[0027] FIG. 11 illustrates the effect of improved encapsulation
efficiency on the resulting immune response due to the cationic
lipid/antigen complex. Anti TC-1 tumor activity was enhanced by
incorporation of E7-lipopeptide in the cationic liposomal
formulation. TC-1 tumor bearing mice (8-12 mice per group) received
a single treatment on day 6 with DOTAP/E7 (containing E7 peptide of
5 or 10 nmols) or DOTAP/E7-lipopeptide (containing 5 nmol peptide)
or DOTAP lipid alone. Mice treated with dextrose (5%) were used as
a negative control. The mean of tumor sizes of each group at day 24
was compared to that of the group which was received DOTAP/E7 (5
nmol) and was analyzed by Student's t-test (*p<0.05,
**p<0.01).
[0028] FIG. 12 is a graph demonstrating that immunization of mice
with DOTAP/E7-lipopeptide induces increased secretion of IFN-y in
CD8.sup.+ T cells.
[0029] FIG. 13 is a graph illustrating increased immunogenicity of
peptide antigen attached to short unrelated amino acid
sequence.
[0030] FIG. 14A is a graph illustrating the expression of
co-stimulatory molecules, CD80 and CD86, on DC2.4 cells after
stimulation with different cationic liposomes.
[0031] FIG. 14B is a graph illustrating the expression of
hydrocarbon chain length dependence of cationic lipids on the
expression of co-stimulatory molecule (CD 80) on DC 2.4 cells.
[0032] FIGS. 15A-B Transcription of chemokines and CD 11c are
upregulated and IL-1 is down regulated by cationic liposomes. (FIG.
15A) Affymetrix microarray analysis showing fold increase in mRNA
levels after DC2. Four cells were treated with 50 .mu.M DOTAP
liposomes for 24 h. (FIG. 15B) RT-PCR showing CCL2 and CCL4 are
upregulated by DOTAP and
1,2-dioleoyl-sn-glycero-3-ethylphosphocholine ("DOEPC") in BMDC
incubated with 50 DOEPC or DOTAP liposomes for 16 h followed by
total RNA extraction and amplification with specific primers (100
ng/mL LPS as positive control).
[0033] FIG. 16 Only cationic liposomes induce the CCL2 release from
the BMDC.
[0034] FIG. 17 DOTAP induces CCL2 release in a dose dependent
manner
[0035] FIG. 18 MAP Kinase inhibitors were used to study the
signaling pathways involved in the DOTAP-induced CCL2 release from
BMDC. On day 6, BMDC were pre-incubated with inhibitors for 20 min,
followed by 75 .mu.M DOTAP liposome treatment for 24 h. The
concentration used in the experiments are: PD (PD-98059), 20 .mu.M;
SB (SB-203580), 10 .mu.M; U (U-0126), 10 .mu.M; PTx (Pertussis
Toxin), 200 ng/mL; PP2, 10 .mu.M; Wort (Wortmannin), 200 nM; GF (GF
109203x), 200 nM. The supernatant was analyzed by ELISA. One
hundred nanograms per millilitre LPS served as a positive
control.
[0036] FIGS. 19A-C DOTAP induces activation of ERK and p38 in BMDC.
(FIG. 19A) Time course study. On day 6, BMDC were seeded in 12-well
plate in the density of 106/mL/well. They were incubated with 75
.mu.M DOTAP liposomes for the indicated time. The cells were
harvested and subjected to Western blotting analysis using
antibodies indicated in the figure. The same membrane was probed
with ERK2 antibody to serve as a loading control. (FIG. 19B)
DOTAP-induced activation of ERK was negatively regulated by p38.
(FIG. 19C) DOTAP-induced ERK activation was mainly through PI-3
kinase and negatively regulated by p38.
[0037] FIGS. 20A-B Down-regulation of ERK gene expression by siRNA
approach attenuates the DOTAP-induced CCL2 release from BMDC. (FIG.
20A) ERK1 gene expression was blocked by siRNA after 24 h treatment
in BMDC. (FIG. 20B) ERK1 blockage by siRNA specifically attenuated
DOTAP-induced CCL2 release from BMDC. DOTAP: 75_M, LPS: 100 ng/mL.
*p<0.05 compared with control siRNA, n=3.
[0038] FIGS. 21A-B DOTAP/E7 formulation induces the accumulation of
CCL2 in the mice draining lymph nodes. On day 0, the mice (n=3)
were injected with DOTAP/E7 formulation (100 nmol of DOTAP and 10
.mu.g of E7 peptide). On indicated days, the mice were sacrificed
and the draining lymph nodes were collected. The draining lymph
nodes were either homogenized in 100 .mu.L ELISA buffer (10% FBS in
PBS) and then analyzed by ELISA (FIG. 21A) or immunochemically
stained by CCL2 antibody (FIG. 21B) as mentioned in the text.
Original magnification: .times.400.
[0039] FIGS. 22A-B Inhibition of ERK both attenuates the CCL2
accumulation in the draining lymph nodes and blocks the anti-tumor
activity of DOTAP/E7 formulation. (FIG. 22A) CCL2 accumulation in
the draining lymph nodes was reciprocally regulated by ERK and p38
pathways. (FIG. 22B) TC-1 tumor growth kinetics on mice that
received DOTAP/E7 co-formulated with or without inhibitor. Mice
(n=5) were injected with TC-1 cells (1.times.10.sup.5/mouse) on day
0. On day 6, they were treated with DOTAP/E7, DOTAP/E7/U-0126,
DOTAP/E7/SB or PBS. Tumor size was measured thereafter. *p<0.05,
compared to the DOTAP/E7.
[0040] FIGS. 23A-E Cationic lipid/antigen complexes effectively
activate human dendritic cells. FIGS. 23, A-E, illustrate
stimulation of CD 80 by DOTAP/E7, CD 83 by DOTAP/E7, CD 86 by
DOTAP/E7, CD 80 by DOEPC/E7 and DOTAP/Cholesterol/E7, and CD 83 by
DOEPC/E7 and DOTAP/Cholesterol/E7 respectively.
[0041] FIGS. 24A-F illustrate the ability of DOTAP/E7 complex to
induce cytokine and chemokine production by human dendritic cells.
FIGS. 24 A-F illustrate production of TNF-.alpha., IL-12, CCL3,
CCL4, CC15, and CCL-19 respectively.
[0042] FIGS. 25A-B illustrate the effect of the cationic
lipid/antigen complex particles size on activation of human
dendritic cells.
DETAILED DESCRIPTION
[0043] One or more specific embodiments of the present invention
will be described below. In an effort to provide a concise
description of these embodiments, all features of an actual
implementation may not be described in the specification. It should
be appreciated that in the development of any such actual
implementation numerous implementation-specific decisions must be
made to achieve the developers' specific goals, which may vary from
one implementation to another. Moreover, it should be appreciated
that such a development effort might be complex and time consuming,
but would nevertheless be a routine undertaking for those of
ordinary skill having the benefit of this disclosure.
[0044] When introducing elements of the present invention (e.g.,
the exemplary embodiments(s) thereof), the articles "a", "an",
"the" and "said" are intended to mean that there are one or more of
the elements. The terms "comprising", "including" and "having" are
intended to be inclusive and mean that there may be additional
elements other than the listed elements.
[0045] One aspect of the present invention provides a cationic
lipid to produce an immune response in a mammal to prevent or treat
disease. The cationic lipid can function independently as an
immunomodulator, in a dose dependent manner, such as for production
of chemokines and/or cytokines, by activating various components of
the MAP kinase signaling pathway. The optimal dose range is
observed to differ within various mammalian species. In the rodent
species for example the optimal cationic lipid dose may range
between 50-300 nmole. The specific doses and compositions described
herein are merely exemplary and one skilled in the art can
determine the doses appropriate for use in a given subject. In
another aspect, the cationic lipid in a low dose range may be
associated with antigens or drugs for presentation to cells of the
immune system while simultaneously stimulating a strong
antigen-specific immune response. In some aspects of the invention,
the antigen is a lipopeptide.
[0046] U.S. Pat. No. 7,303,881 discloses that multiple cationic
lipids complexed with disease-associated antigens were shown to
stimulate a prophylactic immune response that prevented the
specific disease (e.g., HPV-positive cancer) and also a therapeutic
immune response that killed cells expressing the particular antigen
and resulted in an effective treatment of the disease. Presently,
studies were performed to further understand the immunostimulatory
capability of cationic lipids using DOTAP, DOEPC, and
propyl-N,N,N-trimethyl ammonium chloride ("DOTMA"), three cationic
lipids that fall into a broad class of lipids demonstrated to
function as immunostimulators in the above referenced patent. These
studies have led to the discovery that cationic lipids can function
independently as immunodulators within certain low dose ranges or
compositions to stimulate an immune response with (or without)
antigens. When cationic lipids are complexed with an antigen, an
antigen specific immune response is generated.
[0047] In another aspect, the cationic lipid compositions of the
present invention administered under certain dose conditions
presently described stimulate the induction of various components
of the MAP kinase signaling pathway and activate the body's immune
response to fighting disease, while concurrently delivering
antigens to the cells of the immune system. As demonstrated in the
examples below, cationic lipids induce the production of reactive
oxygen species ("ROS") production in a dose dependent manner.
However, beyond the optimal dose of cationic lipid, high ROS
production induces apoptosis in cells of the immune system
dampening the ability of the lipid to generate a strong immune
response. The production of a specific range of ROS, in turn,
results in the production of cytokines and chemokines to regulate
an immune response. Thus, the optimal dose of cationic lipid is an
amount that effectively stimulates levels of ROS production
sufficient to stimulate an increase in the immune response above an
immune response present in the absence of a cationic lipid (while
not stimulating excess ROS production sufficient to induce
significant amounts of apoptosis in immune system cells, i.e.,
enough apoptosis to dampen the immune response) and activates the
MAP kinase signaling pathway. As described above, the optimal dose
may vary among species and is easily determined by one having
ordinary skill in the art.
[0048] In yet another aspect, the cationic lipid, at optimal dose,
is administered in combination with an antigen or antigens. In this
case the cationic lipid/antigen combination is capable of
generating an immune response that is specific to the antigen(s)
delivered in combination with the cationic lipid. The response
generated may include production of specific cytotoxic T cells,
memory T cells, or B cells resulting in the prevention of or
therapeutic response to the specific disease associated with the
antigen(s).
[0049] The cationic lipids of the invention may be in the form of
cationic lipid complexes. The cationic lipid complex can take the
form of various vesicles such as liposomes, micelles, or emulsions.
The cationic lipid complexes may be unilaminar or multilaminar.
When an antigen is included, the antigen may be encapsulated in the
cationic lipid complex or may be unencapsulated. Encapsulated is
understood to mean that the antigen maybe contained within the
internal space of the complex and/or incorporated into the lipid
walls of the complex.
[0050] The invention further relates to a method for producing
these complexes where the method may optionally include the step of
purifying these formulations from excess individual components. For
the production of the antigen complexes of this invention,
inclusion of the purification step is an advantageous
embodiment.
[0051] In certain embodiments, cationic lipid complexes have a net
positive charge and/or a positively charged surface at pH
6.0-8.0.
[0052] The optional "antigen" which may be included with cationic
lipid complexes of the invention may be nucleic acids, peptides,
lipopeptides, proteins, lipoproteins, polysaccharides, and other
macromolecules which may be complexed directly with cationic
lipids. However, cationic drugs (e.g., large cationic protein) can
be directly complexed with an anionic lipid or sequentially
complexed first with anionic lipid or polymer followed by cationic
lipid. The use of this process permits delivery of positive or
neutral charged drugs to cells by the complexes of the present
invention.
[0053] One aspect of the present invention involves the use of the
cationic lipid complexes to stimulate the production of chemokines
and cytokines. Chemokines and cytokines are important regulators of
immune responses. Chemokines were originally identified as potent
chemoattractants for inflammatory cells including neutrophils,
eosinophils, and monocytes/macrophages. Subsequent studies have
revealed that chemokines have profound effects on immune reactions
by regulating the trafficking of dendritic cells and other
lymphocytes into lymphoid organs. Dendritic cells are migratory
cells that sample antigens in the tissue, migrate to the draining
lymph nodes and mature to stimulate the T cell response. CCL2, a
member of the CC chemokines was originally identified as a
chemotactic and activating factor for monocytes/macrophages.
Subsequent studies showed that it can also affect the function of T
cells, natural killer cells, and neutrophils. Further exploration
found that CCL2 was the most potent activator of CD8+ cytotoxic T
lymphocytes ("CTL") activity, when in the presence of the Th1
cytokines, interleukin-12 ("IL-12") and interferon-.gamma.
("IFN-.gamma."). This can be explained by a positive bidirectional
interaction between CCL2 and IFN-.gamma. systems. An absence of
either the cytokine or chemokine may interfere with Thl
polarization and subsequent specific tumor immunity generation.
Another CC chemokine, CCL-4, has also been shown to recruit and
expand dendritic cells in vivo and potentiate the immunogenicity of
plasmid DNA vaccines. Recently, it has been shown that chemokines
enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T
cell-dendritic cell interaction and promote memory CD8+ T cell
generation. A few examples of chemokines that may be stimulated by
the cationic lipid complexes of the present invention are CCL-2,
CCL-3, and CCL-4. Examples of cytokines that may be stimulated by
the cationic lipid complexes of the present invention are IL-12 and
IFN-.gamma.. The inventors contemplate that the cationic lipid
complexes of the present invention may stimulate chemokines and
cytokines in addition to those disclosed in this specification.
[0054] In a further aspect, the cationic lipid complexes of the
present invention stimulate an immune response by activating
cellular kinase pathways such as, for example, the
extracellular-signal-regulated kinase (ERK) pathway (also known as
mitogen actived (MAP) kinase pathway), p38 pathway, or phosphatidyl
inositol-3 (PI-3) pathway. These pathways, in turn, may regulate
the stimulation of the immune response and the production of
cytokines and chemokines. These pathways are well known by those
having skill in the art.
[0055] Cationic lipid complexes of the present invention may
regulate T cell activity to stimulate an immune response. There are
three classes of T cells: helper T cells, killer T cells and
regulatory T cells. These three classes of T cells work together to
coordinate the cellular immune response. The cytotoxic
T-lymphocytes ("CTL"), also known as killer T cells or CD8+
T-cells, are responsible for attacking cells that express foreign
or tumor antigens. Regulatory T cells are believed to be
responsible for dampening CTL mediated immunity, although the exact
mechanisms underlying this effect of the regulatory T cells is not
well understood. It is known that decreasing regulatory T cell
activity can result in increased CTL activity leading to a more
robust cellular immunity response. As shown in the examples below,
the cationic lipid complexes of the present invention at optimal
lipid dose compositions may also stimulate a potent immune response
by decreasing the population of regulatory T cells.
[0056] Lipids
[0057] The cationic lipid complexes of the present invention may
form liposomes that are optionally mixed with antigen and may
contain cationic lipids alone or cationic lipids in combination
with neutral lipids. Suitable cationic lipid species include, but
are not limited to: 3-[.beta..sup.4N-(.sup.1N, .sup.8-diguanidino
spermidine)-carbamoyl]cholesterol (BGSC);
3-.beta.[N,N-diguanidinoethyl-aminoethane)-carbamoyl]cholesterol
(BGTC); N,N.sup.1N.sup.2N.sup.3Tetra-methyltetrapalmitylspermine
(cellfectin);
N-t-butyl-N'-tetradecyl-3-tetradecyl-aminopropion-amidine
(CLONfectin); dimethyldioctadecyl ammonium bromide (DDAB);
1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide
(DMRIE);
2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-p-
-ropanaminium trifluorocetate) (DOSPA);
1,3-dioleoyloxy-2-(6-carboxyspermyl)-propyl amide (DOSPER);
4-(2,3-bis-palmitoyloxy-propyl)-1-methyl-1H-imidazole (DPIM)
N,N,N',N'-tetramethyl-N,N'-bis(2-hydroxyethyl)-2,3-dioleoyloxy-1,4-butane-
diammonium iodide) (Tfx-50); N-1-(2,3-dioleoyloxy)
propyl-N,N,N-trimethyl ammonium chloride (DOTMA) or other
N-(N,N-1-dialkoxy)-alkyl-N,N,N-tri substituted ammonium
surfactants; 1,2 dioleoyl-3-(4'-trimethylammonio)
butanol-sn-glycerol (DOBT) or cholesteryl (4'trimethylammonia)
butanoate (ChOTB) where the trimethylammonium group is connected
via a butanol spacer arm to either the double chain (for DOTB) or
cholesteryl group (for ChOTB); DORI
(DL-1,2-dioleoyl-3-dimethylaminopropyl-.beta.-hydroxyethylammonium)
or DORIE
(DL-1,2-O-dioleoyl-3-dimethylaminopropyl-.beta.-hydroxyethylammoniu-
-m) (DOME) or analogs thereof as disclosed in WO 93/03709;
1,2-dioleoyl-3-succinyl-sn-glycerol choline ester (DOSC);
cholesteryl hemi succinate ester (ChOSC); lipopolyamines such as
dioctadecylamidoglycylspermine (DOGS) and dipalmitoyl
phosphatidylethanolamylspermine (DPPES) or the cationic lipids
disclosed in U.S. Pat. No. 5,283,185,
cholesteryl-3.beta.-carboxyl-amido-ethylenetrimethylammonium
iodide, 1-dimethylamino-3-trimethylammonio-DL-2-propyl-choIesteryl
carboxylate iodide, cholesteryl-3-O-carboxyamidoethyleneamine,
cholesteryl-3-O-oxysuccinamido-ethylenetrimethylammonium iodide,
1-dimethylamino-3-trimethylammonio-DL-2-propyl-cholesteryl-3-.beta.-oxysu-
ccinate iodide, 2-(2-trimethylammonio)-ethylmethylamino
ethyl-cholesteryl-3-O-oxysuccinate iodide,
3-.beta.-N-(N',N'-dimethylaminoethane) carbamoyl cholesterol
(DC-chol), and 3-.beta.-N-(polyethyleneimine)-carbamoylcholesterol;
O,O'-dimyristyl-N-lysyl aspartate (DMKE);
O,O'-dimyristyl-N-lysyl-glutamate (DMKD);
1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide
(DMRIE); 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLEPC);
1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC);
1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC);
1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPEPC);
1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSEPC);
1,2-dioleoyl-3-trimethylammonium propane (DOTAP); dioleoyl
dimethylaminopropane (DODAP); 1,2-palmitoyl-3-trimethylammonium
propane (DPTAP); 1,2-distearoyl-3-trimethylammonium propane
(DSTAP), 1,2-myristoyl-3-trimethylammonium propane (DMTAP); and
sodium dodecyl sulfate (SDS). The present invention contemplates
the use of structural variants and derivatives of the cationic
lipids disclosed in this application.
[0058] Certain aspects of the present invention include
non-steroidal cationic lipids having a structure represented by the
following formula:
##STR00001##
wherein in R.sup.1 is a quaternary ammonium group, Y.sup.1 is
chosen from a hydrocarbon chain, an ester, a ketone, and a peptide,
R.sup.2 and R.sup.3 are independently chosen from a saturated fatty
acid, an unsaturated fatty acid, an ester-linked hydrocarbon,
phosphor-diesters, and combinations thereof. DOTAP, DMTAP, DSTAP,
DPTAP, DPEPC, DSEPC, DMEPC, DLEPC, DOEPC, DMKE, DMKD, DOSPA, DOTMA,
are examples of lipids having this general structure.
[0059] In one embodiment, cationic lipids of the invention are
lipids in which bonds between the lipophilic group and the amino
group are stable in aqueous solution. Thus, an attribute of the
complexes of the invention is their stability during storage (i.e.,
their ability to maintain a small diameter and retain biological
activity over time following their formation). Such bonds used in
the cationic lipids include amide bonds, ester bonds, ether bonds
and carbamoyl bonds. Those of skill in the art would readily
understand that liposomes containing more than one cationic lipid
species may be used to produce the complexes of the present
invention. For example, liposomes comprising two cationic lipid
species, lysyl-phosphatidylethanolamine and .beta.-alanyl
cholesterol ester have been disclosed for certain drug delivery
applications [Brunette, E. et al., Nucl. Acids Res., 20:1151
(1992)].
[0060] It is to be further understood that in considering cationic
liposomes suitable for use in the invention and optionally mixing
with antigen, the methods of the invention are not restricted only
to the use of the cationic lipids recited above but rather, any
lipid composition may be used so long as a cationic liposome is
produced and the resulting cationic charge density is sufficient to
activate and induce an immune response.
[0061] Thus, the complexes of the invention may contain other
lipids in addition to the cationic lipids. These lipids include,
but are not limited to, lyso lipids of which
lysophosphatidylcholine (1-oleoyl lysophosphatidylcholine) is an
example, cholesterol, or neutral phospholipids including dioleoyl
phosphatidyl ethanolamine (DOPE) or dioleoyl phosphatidylcholine
(DOPC) as well as various lipophylic surfactants, containing
polyethylene glycol moieties, of which Tween-80 and PEG-PE are
examples.
[0062] The cationic lipid complexes of the invention may also
contain negatively charged lipids as well as cationic lipids so
long as the net charge of the complexes formed is positive and/or
the surface of the complex is positively charged. Negatively
charged lipids of the invention are those comprising at least one
lipid species having a net negative charge at or near physiological
pH or combinations of these. Suitable negatively charged lipid
species include, but are not limited to, CHEMS (cholesteryl
hemisuccinate), NGPE (N-glutaryl phosphatidlylethanolanine),
phosphatidyl glycerol and phosphatidic acid or a similar
phospholipid analog.
[0063] Methods for producing the liposomes to be used in the
production of the lipid comprising drug delivery complexes of the
present invention are known to those of ordinary skill in the art.
A review of methodologies of liposome preparation may be found in
Liposome Technology (CFC Press New York 1984); Liposomes by Ostro
(Marcel Dekker, 1987); Methods Biochem Anal. 33:337-462 (1988) and
U.S. Pat. No. 5,283,185. Such methods include freeze-thaw extrusion
and sonication. Both unilamellar liposomes (less than about 200 nm
in average diameter) and multilamellar liposomes (greater than
about 300 nm in average diameter) may be used as starting
components to produce the complexes of this invention.
[0064] In the cationic liposomes utilized to produce the cationic
lipid complexes of this invention, the cationic lipid is present in
the liposome at from about 10 mole % to about 100 mole % of total
liposomal lipid, or from about 20 mole % to about 80 mole %. The
neutral lipid, when included in the liposome, may be present at a
concentration of from about 0 mole % to about 90 mole % of the
total liposomal lipid, or from about 20 mole % to about 80 mole %,
or from 40 mole % to 80 mole %. The negatively charged lipid, when
included in the liposome, may be present at a concentration ranging
from about 0 mole % to about 49 mole % of the total liposomal
lipid, or from about 0 mole % to about 40 mole %. In one
embodiment, the liposomes contain a cationic and a neutral lipid,
in ratios between about 2:8 to about 6:4. It is further understood
that the complexes of the present invention may contain modified
lipids, protein, polycations or receptor ligands which function as
a targeting factor directing the complex to a particular tissue or
cell type. Examples of targeting factors include, but are not
limited to, asialoglycoprotein, insulin, low density lipoprotein
(LDL), folate and monoclonal and polyclonal antibodies directed
against cell surface molecules. Furthermore, to modify the
circulatory half-life of the complexes, the positive surface charge
can be sterically shielded by incorporating lipophilic surfactants
which contain polyethylene glycol moieties.
[0065] The cationic lipid complexes may be stored in isotonic
sucrose or dextrose solution upon collection from the sucrose
gradient or they may be lyophilized and then reconstituted in an
isotonic solution prior to use. In one embodiment, the cationic
lipid complexes are stored in solution. The stability of the
cationic lipid complexes of the present invention is measured by
specific assays to determine the physical stability and biological
activity of the cationic lipid complexes over time in storage. The
physical stability of the cationic lipid complexes is measured by
determining the diameter and charge of the cationic lipid complexes
by methods known to those of ordinary skill in the art, including
for example, electron microscopy, gel filtration chromatography or
by means of quasi-elastic light scattering using, for example, a
Coulter N4SD particle size analyzer as described in the Examples.
The physical stability of the cationic lipid complex is
"substantially unchanged" over storage when the diameter of the
stored cationic lipid complexes is not increased by more than 100%,
or by not more than 50%, or by not more than 30%, over the diameter
of the cationic lipid complexes as determined at the time the
cationic lipid complexes were purified.
[0066] While it is possible for the cationic lipid to be
administered in a pure or substantially pure form, it is preferable
to present it as a pharmaceutical composition, formulation or
preparation. Pharmaceutical formulations using the cationic lipid
complexes of the invention may comprise the cationic lipid
complexes in a physiologically compatible sterile buffer such as,
for example, phosphate buffered saline, isotonic saline or low
ionic strength buffer such as acetate or Hepes (an exemplary pH
being in the range of about 5.0 to about 8.0). The cationic lipid
complexes may be administered as aerosols or as liquid solutions
for intratumoral, intraarterial, intravenous, intratracheal,
intraperitoneal, subcutaneous, and intramuscular
administration.
[0067] The formulations of the present invention may incorporate
any stabilizer known in the art. Illustrative stabilizers are
cholesterol and other sterols that may help rigidify the liposome
bilayer and prevent disintegration or destabilization of the
bilayer. Also agents such as polyethylene glycol, poly-, and
mono-saccahrides may be incorporated into the liposome to modify
the liposome surface and prevent it from being destabilized due to
interaction with blood-components. Other illustrative stabilizers
are proteins, saccharides, inorganic acids, or organic acids which
may be used either on their own or as admixtures.
[0068] A number of pharmaceutical methods may be employed to
control, modify, or prolong the duration of immune stimulation.
Controlled release preparations may be achieved through the use of
polymer complexes such as polyesters, polyamino acids,
methylcellulose, polyvinyl, poly(lactic acid), and hydrogels to
encapsulate or entrap the cationic lipids and slowly release them.
Similar polymers may also be used to adsorb the liposomes. The
liposomes may be contained in emulsion formulations in order to
alter the release profile of the stimulant. Alternatively, the
duration of the stimulant's presence in the blood circulation may
be enhanced by coating the surface of the liposome with compounds
such as polyethylene glycol or other polymers and other substances
such as saccharides which are capable of enhancing the circulation
time or half life of liposomes and emulsions.
[0069] When oral preparations are required, the cationic lipids may
be combined with typical pharmaceutical carriers known in the art
such as, for example, sucrose, lactose, methylcellulose,
carboxymethyl cellulose, or gum Arabic, among others. The cationic
lipids may also be encapsulated in capsules or tablets for systemic
delivery.
[0070] Administration of the cationic lipid of the present
invention may be for either a prophylactic or therapeutic purpose.
When provided prophylactically, the cationic lipid is provided in
advance of any evidence or symptoms of illness. When provided
therapeutically, the cationic lipid is provided at or after the
onset of disease. The therapeutic administration of the
immune-stimulant serves to attenuate or cure the disease. For both
purposes, the cationic lipid may be administered with an additional
therapeutic agent(s) or antigen(s). When the cationic lipids are
administered with an additional therapeutic agent or antigen, the
prophylactic or therapeutic effect may be generated against a
specific disease.
[0071] The formulations of the present invention, both for
veterinary and for human use, comprise a cationic lipid alone as
described above, and also optionally, with one or more therapeutic
ingredients such as an antigen(s) or drug molecule(s). The
formulations may conveniently be presented in unit dosage form and
may be prepared by any method known in the pharmaceutical art.
[0072] Antigens
[0073] In one embodiment, the cationic lipid is administered
without any additional agents in order to boost or lower various
immune responses, including production of other immune modulators,
and to boost the immune response to fighting disease. In another
embodiment, the cationic lipid is administered in combination with
an antigen or antigens. In this case the objective is to generate
an immune response, which is specific to the antigen(s) delivered
in combination with the cationic lipid. The response generated may
include production of specific cytotoxic T-cells, memory T-cells,
or B-cells resulting in the prevention of or therapeutic response
to the specific disease associated with those antigen(s). The
antigen can be any tumor-associated antigen or microbial antigen or
any other antigen known to one skilled in the art.
[0074] A "tumor-associated antigen," as used herein is a molecule
or compound (e.g., a protein, peptide, polypeptide, lipoprotein,
lipopeptide, glycoprotein, glycopeptides, lipid, glycolipid,
carbohydrate, RNA, and/or DNA) associated with a tumor or cancer
cell and which is capable of provoking an immune response (humoral
and/or cellular) when expressed on the surface of an antigen
presenting cell in the context of an MEW molecule. Tumor-associated
antigens include self antigens, as well as other antigens that may
not be specifically associated with a cancer, but nonetheless
enhance an immune response to and/or reduce the growth of a tumor
or cancer cell when administered to an animal. More specific
embodiments are provided herein.
[0075] A "microbial antigen," as used herein, is an antigen of a
microorganism and includes, but is not limited to, infectious
virus, infectious bacteria, infectious parasites and infectious
fungi. Microbial antigens may be intact microorganisms, and natural
isolates, fragments, or derivatives thereof, synthetic compounds
which are identical to or similar to naturally-occurring microbial
antigens and, preferably, induce an immune response specific for
the corresponding microorganism (from which the naturally-occurring
microbial antigen originated). In a preferred embodiment, a
compound is similar to a naturally-occurring microorganism antigen
if it induces an immune response (humoral and/or cellular) similar
to a naturally-occurring microorganism antigen. Compounds or
antigens that are similar to a naturally-occurring microorganism
antigen are well known to those of ordinary skill in the art such
as, for example, a protein, peptide, polypeptide, lipoprotein,
lipopeptide, glycoprotein, glycopeptides, lipid, glycolipid,
carbohydrate, RNA, and/or DNA. Another non-limiting example of a
compound that is similar to a naturally-occurring microorganism
antigen is a peptide mimic of a polysaccharide antigen. More
specific embodiments are provided herein.
[0076] The term "antigen" is further intended to encompass peptide
or protein analogs of known or wild-type antigens such as those
described in this specification. The analogs may be more soluble or
more stable than wild type antigen, and may also contain mutations
or modifications rendering the antigen more immunologically active.
Antigen can be modified in any manner, such as adding lipid or
sugar moieties, mutating peptide or protein amino acid sequences,
mutating the DNA or RNA sequence, or any other modification known
to one skilled in the art. Antigens can be modified using standard
methods known by one skilled in the art.
[0077] Also useful in the compositions and methods of the present
invention are peptides or proteins which have amino acid sequences
homologous with a desired antigen's amino acid sequence, where the
homologous antigen induces an immune response to the respective
tumor, microorganism or infected cell.
[0078] In one embodiment, the antigen in the cationic lipid complex
comprises an antigen associated with a tumor or cancer, i.e., a
tumor-associated antigen, to make a vaccine to prevent or treat a
tumor. As such, in one embodiment, the tumor or cancer vaccines of
the present invention further comprise at least one epitope of at
least one tumor-associated antigen. In another preferred
embodiment, the tumor or cancer vaccines of the present invention
further comprise a plurality of epitopes from one or more
tumor-associated antigens. The tumor-associated antigens finding
use in the cationic lipid complexes and methods of the present
invention can be inherently immunogenic, or non-immunogenic, or
slightly immunogenic. As demonstrated herein, even tumor-associated
self antigens may be advantageously employed in the subject
vaccines for therapeutic effect, since the subject compositions are
capable of breaking immune tolerance against such antigens.
Exemplary antigens include, but are not limited to, synthetic,
recombinant, foreign, or homologous antigens, and antigenic
materials may include but are not limited to proteins, peptides,
polypeptides, lipoproteins, lipopeptides, lipids, glycolipids,
carbohydrates, RNA and DNA. Examples of such vaccines include, but
are not limited to the treatment or prevention of breast cancer,
head and neck cancer, melanoma, cervical cancer, lung cancer,
prostate cancer gut carcinoma, or any other cancer known in the art
succeptable to immunotherapy, using a cationic lipid in a complex
with a tumor-associated antigen(s). It is also possible to
formulate the antigen with the cationic lipid without encapsulating
in the liposome.
[0079] The cationic lipid complexes of the present invention may be
used in methods to treat or prevent cancer. In such a case, the
mammal to be immunized is injected with the pharmaceutical
formulation containing the liposome with the encapsulated
antigen(s). Examples of cancers that may be treated with the tumor
vaccines include but are not limited to the prevention or treatment
of breast cancer, head and neck cancer, melanoma, cervical cancer,
lung cancer, prostate cancer, gut carcinoma, or any other cancer
known in the art using a cationic lipid and an antigen or multiple
peptide antigens associated with the cancer. It is also possible to
formulate the antigen with the cationic lipid without encapsulating
the antigen in the liposome.
[0080] Tumor-associated antigens suitable for use in the present
invention include both naturally occurring and modified molecules
which may be indicative of single tumor type, shared among several
types of tumors, and/or exclusively expressed or overexpressed in
tumor cells in comparison with normal cells. In addition to
proteins, glycoproteins, lipoproteins, peptides, and lipopeptides,
tumor-specific patterns of expression of carbohydrates,
gangliosides, glycolipids, and mucins have also been documented.
Exemplary tumor-associated antigens for use in cancer vaccines
include protein products of oncogenes, tumor suppressor genes, and
other genes with mutations or rearrangements unique to tumor cells,
reactivated embryonic gene products, oncofetal antigens,
tissue-specific (but not tumor-specific) differentiation antigens,
growth factor receptors, cell surface carbohydrate residues,
foreign viral proteins, and a number of other self proteins.
[0081] Specific embodiments of tumor-associated antigens include,
e.g., mutated or modified antigens such as the protein products of
the Ras p21 protooncogenes, tumor suppressor p53 and HER-2/neu and
BCR-abl oncogenes, as well as CDK4, MUM1, Caspase 8, and Beta
catenin; overexpressed antigens such as galectin 4, galectin 9,
carbonic anhydrase, Aldolase A, PRAME, Her2/neu, ErbB-2 and KSA,
oncofetal antigens such as alpha fetoprotein (AFP), human chorionic
gonadotropin (hCG); self antigens such as carcinoembryonic antigen
(CEA) and melanocyte differentiation antigens such as Mart 1/Melan
A, gp100, gp75, Tyrosinase, TRP1 and TRP2; prostate associated
antigens such as PSA, PAP, PSMA, PSM-P1 and PSM-P2; reactivated
embryonic gene products such as MAGE 1, MAGE 3, MAGE 4, GAGE 1,
GAGE 2, BAGE, RAGE, and other cancer testis antigens such as
NY-ES01, SSX2 and SCP1; mucins such as Muc-1 and Muc-2;
gangliosides such as GM2, GD2 and GD3, neutral glycolipids and
glycoproteins such as Lewis (y) and globo-H; and glycoproteins such
as Tn, Thompson-Freidenreich antigen (TF) and sTn. Also included as
tumor-associated antigens herein are whole cell and tumor cell
lysates as well as immunogenic portions thereof, as well as
immunoglobulin idiotypes expressed on monoclonal proliferations of
B lymphocytes for use against B cell lymphomas.
[0082] Tumor-associated antigens and their respective tumor cell
targets include, e.g., cytokeratins, particularly cytokeratin 8, 18
and 19, as antigens for carcinoma. Epithelial membrane antigen
(EMA), human embryonic antigen (HEA-125), human milk fat globules,
MBr1, MBr8, Ber-EP4, 17-1A, C26 and T16 are also known carcinoma
antigens. Desmin and muscle-specific actin are antigens of myogenic
sarcomas. Placental alkaline phosphatase, beta-human chorionic
gonadotropin, and alpha-fetoprotein are antigens of trophoblastic
and germ cell tumors. Prostate specific antigen is an antigen of
prostatic carcinomas, carcinoembryonic antigen of colon
adenocarcinomas. HMB-45 is an antigen of melanomas. In cervical
cancer, useful antigens could be encoded by human papilloma virus.
Chromagranin-A and synaptophysin are antigens of neuroendocrine and
neuroectodermal tumors. Of particular interest are aggressive
tumors that form solid tumor masses having necrotic areas. The
lysis of such necrotic cells is a rich source of antigens for
antigen-presenting cells, and thus the subject therapy may find
advantageous use in conjunction with conventional chemotherapy
and/or radiation therapy.
[0083] In one embodiment, the human papillomavirus HPV antigens are
used. A specific HPV antigen that used as a tumor-associated
antigen is HPV subtype 16 E7. HPV E7 antigen-cationic lipid
complexes are effective at preventing and treating cervical cancer.
In addition, a genetically engineered E7 protein, i.e., Elm
protein, having antigenic activity, but without tumorigenic
activity, is an effective tumor-associated antigen. Elm-cationic
lipid complexes induce cellular immunity to cause complete
regression of established tumors and, thus, are useful as potent
anti-cervical cancer vaccines.
[0084] Tumor-associated antigens can be prepared by methods well
known in the art. For example, these antigens can be prepared from
cancer cells either by preparing crude extracts of cancer cells
(e.g., as described in Cohen et al., Cancer Res., 54:1055 (1994)),
by partially purifying the antigens, by recombinant technology, or
by de novo synthesis of known antigens. The antigen may also be in
the form of a nucleic acid encoding an antigenic peptide in a form
suitable for expression in a subject and presentation to the immune
system of the immunized subject. Further, the antigen may be a
complete antigen, or it may be a fragment of a complete antigen
comprising at least one epitope.
[0085] Antigens derived from pathogens known to predispose to
certain cancers may also be advantageously included in the cancer
vaccines of the present invention. It is estimated that close to
16% of the worldwide incidence of cancer can be attributed to
infectious pathogens; and a number of common malignancies are
characterized by the expression of specific viral gene products.
Thus, the inclusion of one or more antigens from pathogens
implicated in causing cancer may help broaden the host immune
response and enhance the prophylactic or therapeutic effect of the
cancer vaccine. Pathogens of particular interest for use in the
cancer vaccines provided herein include the, hepatitis B virus
(hepatocellular carcinoma), hepatitis C virus (heptomas), Epstein
Barr virus (EBV) (Burkitt lymphoma, nasopharynx cancer, PTLD in
immunosuppressed individuals), HTLVL (adult T cell leukemia),
oncogenic human papilloma viruses types 16, 18, 33, 45 (adult
cervical cancer), and the bacterium Helicobacter pylori (B cell
gastric lymphoma). Other medically relevant microorganisms that may
serve as antigens in mammals and more particularly humans are
described extensively in the literature, e.g., C. G. A Thomas,
Medical Microbiology, Bailliere Tindall, Great Britain 1983, the
entire contents of which is hereby incorporated by reference.
[0086] In another embodiment, the antigen in the cationic lipid
complex comprises an antigen derived from or associated with a
pathogen, i.e., a microbial antigen. As such, in one embodiment,
the pathogen vaccines of the present invention further comprise at
least one epitope of at least one microbial antigen. Pathogens that
may be targeted by the subject vaccines include, but are not
limited to, viruses, bacteria, parasites and fungi. In another
embodiment, the pathogen vaccines of the present invention further
comprise a plurality of epitopes from one or more microbial
antigens.
[0087] The microbial antigens finding use in the cationic lipid
complexes and methods may be inherently immunogenic, or
non-immunogenic, or slightly immunogenic. Exemplary antigens
include, but are not limited to, synthetic, recombinant, foreign,
or homologous antigens, and antigenic materials may include but are
not limited to proteins, peptides, polypeptides, lipoproteins,
lipopeptides, lipids, glycolipids, carbohydrates, RNA, and DNA.
[0088] Exemplary viral pathogens include, but are not limited to,
viruses that infect mammals, and more particularly humans. Examples
of virus include, but are not limited to: Retroviridae (e.g., human
immunodeficiency viruses, such as HIV-1 (also referred to as
HTLV-III, LAV or HTLV-III/LAV, or HIV-III; and other isolates, such
as HIV-LP; Picomaviridae (e.g. polio viruses, hepatitis A virus;
enteroviruses, human Coxsackie viruses, rhinoviruses, echoviruses);
Calciviridae (e.g. strains that cause gastroenteritis); Togaviridae
(e.g. equine encephalitis viruses, rubella viruses); Flaviridae
(e.g. dengue viruses, encephalitis viruses, yellow fever viruses);
Coronoviridae (e.g. coronaviruses); Rhabdoviradae (e.g. vesicular
stomatitis viruses, rabies viruses); Coronaviridae (e.g.
coronaviruses); Rhabdoviridae (e.g. vesicular stomatitis viruses,
rabies viruses); Filoviridae (e.g. ebola viruses); Paramyxoviridae
(e.g. parainfluenza viruses, mumps virus, measles virus,
respiratory syncytial virus); Orthomyxoviridae (e.g. influenza
viruses); Bungaviridae (e.g. Hantaan viruses, bunga viruses,
phleboviruses and Nairo viruses); Arena viridae (hemorrhagic fever
viruses); Reoviridae (e.g. reoviruses, orbiviurses and
rotaviruses); Bimaviridae; Hepadnaviridae (Hepatitis B virus);
Parvovirida (parvoviruses); Papovaviridae (papilloma viruses,
polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae
herpes simplex virus (HSV) 1 and 2, varicella zoster virus,
cytomegalovirus (CMV), herpes virus; Poxyiridae (variola viruses,
vaccinia viruses, pox viruses); and Iridoviridae (e.g. African
swine fever virus); and unclassified viruses (e.g. the etiological
agents of Spongiform encephalopathies, the agent of delta hepatitis
(thought to be a defective satellite of hepatitis B virus), the
agents of non-A, non-B hepatitis (class 1=internally transmitted;
class 2=parenterally transmitted (i.e. Hepatitis C); Norwalk and
related viruses, and astroviruses).
[0089] Also, gram negative and gram positive bacteria may be
targeted by the subject compositions and methods in vertebrate
animals. Such gram positive bacteria include, but are not limited
to Pasteurella species, Staphylococci species, and Streptococcus
species. Gram negative bacteria include, but are not limited to,
Escherichia coli, Pseudomonas species, and Salmonella species.
Specific examples of infectious bacteria include but are not
limited to: Helicobacter pyloris, Borella burgdorferi, Legionella
pneumophiliaii, Mycobacteria sps (e.g. M. tuberculosis, M. avium,
M. intracellulare, M. kansaii, M. gordonae), Staphylococcus aureus,
Neisseria gonorrhoeae, Neisseria meningitidis, Listeria
monocytogenes, Streptococcus pyogenes (Group A Streptococcus),
Streptococcus agalactiae (Group B Streptococcus), Streptococcus
(viridans group), Streptococcus faecalis, Streptococcus bovis,
Streptococcus (anaerobic sps.), Streptococcus pneumoniae,
pathogenicCampylobacter sp., Enterococcus sp., Haemophilus
infuenzae, Bacillus antracis, corynebacterium diphtherias,
corynebacterium sp., Erysipelothrix rhusiopathiae, Clostridium
perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella
pneumoniae, Pasturella multocida, Bacteroides sp., Fusobacterium
nucleatumii, Streptobacillus moniliformis, Treponema pallidium,
Treponema pertenue, Leptospira, Rickettsia, and Actinomyces
israelii.
[0090] Polypeptides of bacterial pathogens which may find use as
sources of microbial antigens in the subject compositions include
but are not limited to an iron-regulated outer membrane protein,
("IROMP"), an outer membrane protein ("OMP"), and an A-protein of
Aeromonis salmonicida which causes furunculosis, p57 protein of
Renibacterium salmoninarum which causes bacterial kidney disease
("BKD"), major surface associated antigen ("msa"), a surface
expressed cytotoxin ("mpr"), a surface expressed hemolysin ("ish"),
and a flagellar antigen of Yersiniosis; an extracellular protein
("ECP"), an iron-regulated outer membrane protein ("IROMP"), and a
structural protein of Pasteurellosis; an OMP and a flagellar
protein of Vibrosis anguillarum and V. ordalii; a flagellar
protein, an OMP protein, aroA, and purA of Edwardsiellosis ictaluri
and E. tarda; and surface antigen of Ichthyophthirius; and a
structural and regulatory protein of Cytophaga columnari; and a
structural and regulatory protein of Rickettsia. Such antigens can
be isolated or prepared recombinantly or by any other means known
in the art.
[0091] Examples of pathogens further include, but are not limited
to, fungi that infect mammals, and more particularly humans.
Examples of fungi include, but are not limited to: Cryptococcus
neoformansi, Histoplasma capsulatum, Coccidioides immitis,
Blastomyces dermatitidis, Chlamydia trachomatis, Candida albicans.
Examples of infectious parasites include Plasmodium such as
Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and
Plasmodium vivax. Other infectious organisms (i.e. protists)
include Toxoplasma gondii. Polypeptides of a parasitic pathogen
include but are not limited to the surface antigens of
Ichthyophthirius.
[0092] Other medically relevant microorganisms that serve as
antigens in mammals and more particularly humans are described
extensively in the literature, e.g., see C. G. A Thomas, Medical
Microbiology, Bailliere Tindall, Great Britain 1983, the entire
contents of which is hereby incorporated by reference. In addition
to the treatment of infectious human diseases and human pathogens,
the compositions and methods of the present invention are useful
for treating infections of nonhuman mammals. Many vaccines for the
treatment of non-human mammals are disclosed in Bennett, K.
Compendium of Veterinary Products, 3rd ed. North American
Compendiums, Inc., 1995; see also WO 02/069369, the disclosure of
which is expressly incorporated by reference herein.
[0093] Exemplary non-human pathogens include, but are not limited
to, mouse mammary tumor virus ("MMTV"), Rous sarcoma virus ("RSV"),
avian leukemia virus ("ALV"), avian myeloblastosis virus ("AMV"),
murine leukemia virus ("MLV"), feline leukemia virus ("FeLV").
murine sarcoma virus ("MSV"), gibbon ape leukemia virus ("GALV"),
spleen necrosis virus ("SNV"), reticuloendotheliosis virus ("RSV"),
simian sarcoma virus ("SSV"), Mason-Pfizer monkey virus ("MPMV"),
simian retrovirus type 1 ("SRV-1"), lentiviruses such as HTV-1,
HIV-2, SIV, Visna virus, feline immunodeficiency virus ("FIV"), and
equine infectious anemia virus ("EIAV"), T-cell leukemia viruses
such as HTLV-1, HTLV-II, simian T-cell leukemia virus ("STLV"), and
bovine leukemia virus ("BLV"), and foamy viruses such as human
foamy virus ("HFV"), simian foamy virus ("SFV") and bovine foamy
virus ("BFV").
[0094] In some embodiments, "treatment," "treat," and "treating,"
as used herein with reference to infectious pathogens, refer to a
prophylactic treatment which increases the resistance of a subject
to infection with a pathogen or decreases the likelihood that the
subject will become infected with the pathogen; and/or treatment
after the subject has become infected in order to fight the
infection, e.g., reduce or eliminate the infection or prevent it
from becoming worse.
[0095] Microbial antigens can be prepared by methods well known in
the art. For example, these antigens can be prepared directly from
viral and bacterial cells either by preparing crude extracts, by
partially purifying the antigens, or alternatively by recombinant
technology or by de novo synthesis of known antigens. The antigen
may also be in the form of a nucleic acid encoding an antigenic
peptide in a form suitable for expression in a subject and
presentation to the immune system of the immunized subject.
Further, the antigen may be a complete antigen, or it may be a
fragment of a complete antigen comprising at least one epitope.
[0096] In order to improve incorporation of the antigen into the
cationic lipid vesicles and also to improve delivery to the cells
of the immune system, the antigen may be modified to increase its
hydrophobicity or the negative charge on the antigen.
Hydrophobicity of an antigen may be increased such as, for example,
by conjugating to a lipid chain or hydrophobic amino acids in order
to improve it's the antigen's solubility in the hydrophobic acyl
chains of the cationic lipid, while maintaining the antigenic
properties of the molecule. The modified antigen can be a
lipoprotein, a lipopeptide, a protein or peptide modified with an
amino acid sequence having increased hydrophobicity, and
combinations thereof. The modified antigen may have a linker
conjugated between the lipid and the antigen such as, for example,
an N-terminal a or c-palmitoyl lysine may be connected to antigen
via a dipeptide serine-serine linker. As discussed in greater
detail below, the DOT AP/E7-lipopeptide complex exhibited an
enhanced functional antigen-specific CD8.sup.+ T lymphocyte
response in vivo compared to the DOTAP/E7 formulation. Further, the
antigen may be manipulated to increase its negative charge by
altering the formulation buffer in which the antigen is
encapsulated into the cationic lipid complexes or by covalently
attaching anionic moieties such as, for example, anionic amino
acids to the antigen.
[0097] As demonstrated in Example 1 (below) immunogenicity of the
E7 antigen was increased by covalently modifying the antigen. It
was possible to covalently attach to the antigen an amino acid
sequence such that the resulting antigen amino acid sequence is not
found in the parent protein from which the antigen was derived.
Studies were performed to demonstrate that the modified antigen
provided superior MHC class I binding affinity compared to the
native antigen. This superior binding affinity as demonstrated,
translated to the generation of a superior in-vivo anti tumor
immune response against HPV-positive TC-1 tumors. The present
invention will be further appreciated in light of the following
examples.
EXAMPLES
Example 1
[0098] Effective Stimulation of the Immune System and
Antigen-Delivery to the Antigen Presenting Cells by Specific Dose
Compositions of Cationic Lipids Leads to a Potent Immune Response
in the Prevention and Treatment of Disease
[0099] 1. Preparation of liposomes for use as an immune system
stimulant including cationic lipid (for example, DOTAP) alone, or
cationic liposomes incorporating an antigen (for example, HPV
protein E7 peptide antigen).
[0100] Cell culture grade water (commercially available from
Cambrex of Walkersville, Md.) or phosphate buffered saline was used
in all liposome preparation procedures. The E7 antigen was the
H-2D.sup.b restricted CTL epitope (amino acid 49-57, RAHYNIVTF
[SEQ. ID. NO. 1]) derived from HPV 16 E7 protein (synthesized by
the University of Pittsburgh, Molecular Medicine Institute,
Pittsburgh, Pa.).
[0101] Liposomes used these studies were made using lipid films.
Lipid films were made in glass vials by (1) dissolving the lipids
in chloroform, and (2) evaporating the chloroform solution under a
steady stream of dry nitrogen gas. Traces of organic solvent were
removed by keeping the films under vacuum overnight. The lipid
films were then hydrated for 12 h by adding the required amount of
water or buffer to make a final concentration of 10 mg/mL. The
suspensions were then sonicated in a bath type sonicator for 10 min
followed by extrusion through 400, 200 and 100 nm membrane filters
(commercially available from Hamilton Co., Reno, Nev.) and stored
at 4.degree. C. For the preparation of DOTAP/E7, the lipid film was
rehydrated by an aqueous solution of E7 peptide. Other methods used
in general liposome preparation that are well known to those
skilled in the art may also be used.
[0102] 2. IL-12 and TNF-.alpha. production by lymph node cells and
dendritic cells is stimulated after treatment with cationic
lipids
[0103] In order to elucidate the immunostimulatory mechanism of the
cationic lipid DOTAP and to further characterize its
immuno-stimulatory activity it is important to assess whether DOTAP
can induce proper Thl cytokine production to further enhance the
immune response. Thus, we examined cytokine production by bone
marrow derived dendritic cells ("BMDC") following DOTAP
stimulation. After six days culture in vitro in the presence of
recombinant mGM-CSF and mIL-4, BMDC (10.sup.6 cells in 2 mL per
well) were stimulated with medium control, DOTAP liposomes, LPD
(cationic lipid complexed DNA and protamine) or lipopolysaccaride
(LPS) at 0.1 .mu.g /mL for 20 h at 37.degree. C. IL-12 and
TNF-.alpha. production in supernatant were analyzed by BD ELISA
Set. LPD and LPS were used as positive controls. The bacterial DNA
in LPD contains CpG motifs known to activate the immune system via
toll-like-receptors and stimulate TNF-.alpha.. Culture supernatant
was harvested and IL-12 and TNF-a cytokine levels were assessed by
ELISA. In FIG. 1, IL-12, but not TNF-.alpha., production increased
in response to DOTAP concentration. This indicates that, in
addition to dendritic cells, other cell types, e.g. T cells, may
also be involved in the Th1 cytokine production stimulated by DOTAP
liposome observed in vivo. Further, the fact that the cationic
lipids did not induce significant levels of the pro-inflammatory
cytokine TNF-.alpha., suggests that the immunostimulatory mechanism
may be independent of the toll-like-receptor pathway.
[0104] 3. An antigen specific CTL immune response is induced in a
lipid dose dependent manner by a cationic lipid/antigen
complex.
[0105] C57BL/6 female mice were immunized with DOTAP/E7
formulations at days 0 and 7. Various concentrations of DOTAP were
used, however the concentration of the HPV-16 E7 antigen was
maintained at a 10 .mu.g dose. The E7 antigen was the H-2 D.sup.b
restricted CTL epitope (amino acid 49-57, RAHYNIVTF (SEQ. ID. NO.
1) derived from HPV 16 E7 protein. Seven days after the last
immunization, mice were sacrificed and splenocytes were harvested
and dissociated. After removal of RBC, total splenocyte population
(responder cells) was stimulated for 5 days with E7 peptide (10
.mu.g /mL) in the presence of 40 U/mL recombinant IL-2
(commercially available from R&D systems of Minneapolis, Minn.)
in complete RPMT-1640 medium. After in vitro CTL expansion,
responder cells were ready to be used as CTL effectors. TC-1 cell
line was used as target cells in this assay. TC-1 cells are C57BL/6
mouse lung epithelial cells transformed with HPV 16 E6 and E7
oncogenes and the activated H-ras. To discriminate between
effectors and target, TC-1 cells were labeled with PKH-67
(commercially available from Sigmaof St. Louis, Mo.) according to
manufacturer's instructions. Effectors and labeled targets were
plated into 96-well plates at various effector:target (E:T) ratios
and the lysis reactions were carried out for 4 h at 37.degree. C.
Cells were then harvested and stained with propidium iodide (PI)
for analysis on a BD FACSCanto digital flow cytometer (commercially
available from BD Biosciences of San Diego, Calif.). Percentage of
E7-specific lysis was determined by the percentage of PI positive
cells within the FL1 (PKH-67) positive region.
[0106] Turning now to FIG. 2, it is observed that mice that
received the DOTAP/E7 at 100 nmoles of DOTAP exhibited significant
CTL activity resulting in specific killing of TC-1 cells while mice
that received DOTAP/E7 at 600 nmoles of DOTAP showed a
significantly reduced killing effect indicating a cationic lipid
dose response effect. Mice that received DOTAP/E7 at 15 nmoles of
DOTAP did not result in CTL activity that was significantly
different from control mice treated with PBS. We confirmed this
killing was E7-specific by incubating effector cells from groups
that received the optimal dose of DOTAP with HPV E7-negative BL6
cells as targets, and negligible cell killing resulted. In addition
to CTL mediated killing, we also investigated natural killer ("NK")
cell mediated cytotoxicity. NK cells are able to destroy tumor
cells without deliberate immunization or activation and they also
play an important role in innate immune responses [Wu, J and
Lanier, L L, Natural killer cells and cancer. Adv Cancer Res 90:127
(2003); and Lodoen, M B, and Lanier, L L, Natural killer cells as
an initial defense against pathogens. Curr Opin Immunol 18:391
(2006)]. Mice that received DOTAP/E7 complex, at various doses of
DOTAP exhibited significant killing against YAC-1 cells, an NK
susceptible target.
[0107] 4. Administration of a cationic lipid/antigen complex
induces in vivo CD8+ and CD4+ T-cell production in a lipid dose
dependent manner and migration into the microenvironment of E-7
positive tumors
[0108] In order to understand whether the optimal DOTAP/E7
formulation induces the production of T-lymphocytes (T-cells) and
if the T-lymphocyes would migrate effectively to the site of cells
expressing the E7 antigen, immunohistochemical examination of
tumor-infiltrating T lymphocytes was performed (FIG. 3). C57BL/6
female mice 6-7 weeks old were purchased from Charles River
Laboratories (Wilmington, Mass.) and were used in all animal
studies. Subcutaneous HPV-positive tumors were established by
injecting TC-1 cells (10.sup.5 cells) into the hair-trimmed flank
of the mouse on day 0. On day 6, mice (n=6-12) were subcutaneously
injected with 150 .mu.L of selected formulations of DOTAP/E7
(15,100, 600 nmole), each containing 10 .mu.g of the E7
peptide.
[0109] Solid HPV-positive tumors were excised from the mice and
dissected on day 14 and embedded in Tissue-Tek.RTM. OCT compound
(commercially available from Sakura Finetek of Torrance, Calif.)
(followed by cryosection preparation). Samples were cut into 8
.mu.m thick sections by a cryostat (commercially available from H/I
Hacker Instruments & Industries Inc.). FITC-conjugated anti-CD8
and anti-CD4 antibodies (commercially available from Miltenyi
Biotec Inc. of Auburn, Calif) were used to determine
tumor-infiltrating T cells followed by counterstaining nuclei with
DAPI. Images of the sections were taken with a Leica SP2 confocal
microscope.
[0110] TUNEL assays were conducted using a TACSTM TdT Kit
(commercially available from R&D Systems of Minneapolis, Minn.)
and developed with DAB according to manufacturer's instructions.
Samples were imaged with a Nikon Microphot SA microscope.
[0111] As shown in FIG. 3, a high proportion of CD8+ T lymphocyte
(.about.5%) were found in mice that received DOTAP/E7 at 100 nmole
(FIG. 3B) compared to the untreated mice (FIG. 3A) and those that
received high dose DOTAP composition (600 nmole, FIG. 3C). A
similar result was found for CD4+ T cells, (FIGS. 3E-F). The TUNEL
assay for determining apoptosis was also performed in some tumor
cryosections. In FIG. 3H, after mice were treated with the 100 nmol
dose of lipid in the DOTAP/E7 complex, a TUNEL-positive reaction
was observed in the condensed and fragmented nuclei of the tumor
cells of those mice as compared to the untreated mice (FIG. 3G) and
high lipid dose group (FIG. 31), which exhibited normal and vital
tumor cells, A similar dose response effect of cationic lipid dose
on T-lymphocyte production is observed to the dose response effect
on the antigen specific CTL-response described above in section 3
entitled "An antigen specific CTL immune response is induced in a
lipid dose dependent manner by a cationic lipid/antigen
complex".
[0112] 5. Administration of a cationic lipid/antigen complex
induces humoral immunity.
[0113] FIG. 4 shows the results of injecting mice with a cationic
lipid/antigen complex containing DOTAP and the protein antigen,
ovalbumin. Mice were evaluated for the ability of the complex to
stimulate B-cell activity and to induce antibody production, also
known as the humoral immune response. The humoral response was
evaluated by monitoring IgG antibody formation. As illustrated by
FIG. 4, DOTAP/ovalbumin complexes elicited a humoral response in a
dose dependent manner. These data suggest that DOTAP formulations
may be used to stimulate both cellular and humoral immune
responses.
[0114] 6. Administration of a cationic lipid/antigen complex
reduces T-regulatory cell populations in a lipid dose dependent
manner.
[0115] Regulatory T cells are thought to dampen T-cell immunity to
tumour-associated antigens and to be the main obstacle tempering
successful immunotherapy and active vaccination. Thus, we
investigated the ability of DOTAP/E7 in a therapeutic vaccine
formulation at its optimal dose to break the immune tolerance
maintained by T regulatory cells in tumor-bearing mice, thus
enhancing the T-cell immunity to tumor associated antigens. All
anti-mouse antibodies used for flow cytometry analysis were
purchased from and are commercially available from BD Pharmingen
(San Diego, Calif) or eBioscience, Inc. (San Diego, Calif.). Spleen
cells were harvested and dissociated by using 1 mg/ml collagenase
and a 70 .mu.m cell strainer. After removal of red blood cells
(RBC), single cell suspensions were stained with
fluorescent-labeled monoclonal anti-CD4 (RM4-5), anti-CD8a
(53-6.7), anti-CD3e (145-2c11), anti-NK1.1 (pk136) and anti-CD25
(pc61.5) antibodies for 30 min at 4.degree. C. After fixation and
permeabilization using the Cytofix/Cytoperm.TM. kit (BD Pharmingen)
according to the manufacturer's instruction, cells were stained
with anti-Foxp3 (FJK-165) in 50 .mu.l of Perm/Wash.TM. buffer for
30 min at 4.degree. C. The cells were washed two more times in
Perm/Wash.TM. buffer and then finally resuspended in 300 pt stain
buffer and analyzed on a BD FACSCanto digital flow cytometer
(commercially available from BD Biosciences of San Diego, Calif.).
As shown in FIG. 5, spleen cells harvested from mice that received
DOTAP/E7 complex (100 nmole DOTAP) but not the high dosage (600
nmole DOTAP) animals exhibited lower amounts of T-reg cell
subpopulations (Foxp3+, CD25+ and CD25+/Foxp3+) compared to
untreated tumor-bearing mice.
[0116] In Table 1, ten representative experiments for T-reg
analysis are summarized. The population of CD4+ T cells
significantly increased in spleen cells after mice received optimal
DOTAP/E7 treatment, a similar increase was also found in CD8+ T
cells (data not shown). In addition, significant decreases of T-reg
populations (CD4+/Foxp3+ and CD4+/CD25+/Foxp3+) were found in this
treatment group. It was especially evident that die reduced
anti-tumor activity of DOTAP/E7 at high DOTAP dose was associated
with increased T-reg cell population. A dose response effect of the
cationic lipid is again observed. This result indicates that
cationic lipid composition used in the immunotherapy at an optimal
dose of lipid is able to possibly enhance the observed immune
response to the specific cancer by breaking tolerance in
tumor-bearing mice and to stimulate proliferation of functional
CD4+ and CD8+ antigen-specific T lymphocytes while suppressing the
T-reg cell population.
[0117] 7. Kinetics of TC-1 HPV-positive tumor growth in mice
treated with DOTAP/E7 compositions at varying doses of DOTAP.
[0118] In FIG. 6, mice were subcutaneously injected with TC-1 cells
on day 0 in order to induce the growth of HPV-positive tumors. The
mice received DOTAP/E7 compositions containing 10 E7 peptide
subcutaneously on the opposite side of the abdomen on day 6. DOTAP
lipid concentration in the complex varied from 3 to 600 nmole (3,
15, 30, 75, 150, 300, and 600 nmole). Low dose of DOTAP (15 nmole)
showed partial tumor inhibition effect (P<0.05) compared to the
untreated control on day 23, while DOTAP at 30, 150 or 300 nmol
exhibited an enhanced efficacy (P<0.01). DOTAP at 75 nmol showed
the most significant tumor regression effect (P<0.001). Again,
mice given a high dose of DOTAP (600 nmol) did not show anti-tumor
activity, confirming that DOTAP liposomes at a high dose might have
induced a negative regulation to the immune response. In addition,
DOTAP liposomes at the 100 nmole dose, but without E7 peptide, did
not show significant inhibition of tumor growth, indicating that
the anti-tumor effect was antigen specific.
[0119] 8. DOTAP/E7 complex is taken up mainly by dendritic cells
after injection and induces dendritic cell activation and migration
to the draining lymph node.
[0120] Naive mice (n=4-6) were injected with PBS control (FIGS. 7
A, C and E) or DOTAP/E7 containing 100 nmols total lipid with
0.5%1-Oleoyl-2-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-3-tr-
imethylammonium propane ("NBD-DOTAP") (FIGS. 7B, D, and F). At 4 h
after the injection, draining lymph node cells were prepared and
stained with appropriate antibodies to surface markers. The
co-expression of NBD and CD11c (FIGS. 7A and B) or CD86 (FIGS. 7 C
and D) were analyzed within total lymph node cells whereas the
co-expression of NBD and CD8 (FIGS. 7E and F) were gated and
analyzed within CD3.sup.+ population. The numbers represented the
percentages of cells in the quadrants. Draining lymph node cells
were harvested and analyzed by flow cytometry at different time
points post injection. The numbers of CD11c.sup.+ cells among total
lymph node cells increased by more than 2.5-fold compared to
untreated mice 4 h after NBD-DOTAP/E7 injection (FIGS. 7A and B).
The expression of the costimulatory molecule, CD86 on the NBD.sup.+
cells was investigated and NBD.sup.+ cells demonstrated high levels
of CD86 (FIGS. 7 C and D), indicating that suncutaneous injection
of DOTAP induced dendritic cell activation. NBD uptake by other
cell types such as T lymphocytes was also investigated by
costaining with anti-CD3, CD4 and CD8 antibodies. CD3.sup.+ cells
were gated and analyzed in (FIGS. 7E and F) and showed no NBD
uptake after NBD-DOTAP injection. The results clearly demonstrated
that NBD-DOTAP is mainly taken up by dendritic cells (.about.80%)
soon after immunization and DOTAP induces migration of activated
dendritic cells to the draining lymph node, resulting in dendritic
cell-T cell interactions and eliciting strong T-cell responses.
[0121] 9. Immunization with DOTAP/E7 complex formulated with one
particularly advantageous dose DOTAP elicits functional CD8.sup.+ T
cells.
[0122] IFN-.gamma. secreted by activated T cells or NK cells are
known to play important roles in Th1 type immune response as well
as inducing CTL response. To assess whether the functional
CD8.sup.+ T lymphocytes induced by DOTAP/E7 vaccination would be
able to produce the essential cytokine, spleen cells from control
or immunized mice were isolated at one week after the final
immunization and incubated with 5 .mu.g/ml E7 peptide or without
peptide for 6 h followed by intracellular staining of IFN-.gamma..
As depicted in FIG. 8, the number of IFN-.gamma. producing
CD8.sup.+ cells were significantly higher in mice that received E7
formulated at the optimal lipid dose of DOTAP and LPD positive
control than the negative control group. IFN-.gamma. production by
the CD8.sup.+ cells occurred in an E7-specific manner. These
results show that DOTAP at optimal dose is a potent vaccine
adjuvant for the induction of CTL as well as generation of
IFN-.gamma. producing CD8.sup.+ T lymphocytes in the systemic
lymphoid organs.
[0123] 10. Comparison of the anti-tumor efficacy of cationic
lipid/E7 complexes with the anti-tumor activity of E7 formulated in
leading adjuvants known to induce antigen specific CTL
activity.
[0124] To compare the efficacy of cationic lipid/E7 formulations
with other adjuvants to induce an immune response to a tumor, 6-12
tumor-bearing mice per formulation were treated, six days after
establishing tumors, with E7 peptide formulated liposomes comprised
of (1) cationic lipid (DOTAP, DOEPC and DOTMA), at the 100
nmoledose composition of cationic lipid, (2) anionic lipid (DOPG),
or (3) adjuvants (complete Freund adjuvant ("CFA") or CpG ODN1826).
In FIG. 9, mice receiving both adjuvants as well as the cationic
lipid formulations showed effective inhibition of tumor growth
compared to the control group on day 26. Mice that received the
anionic lipid DOPG/E7 did not show tumor regression. Mice receiving
optimal DOTAP/E7 and DOEPC formulations exhibited a better
anti-cancer activity (p<0.01) compared to those receiving CpG/E7
or CFA/E7 formulations. Mice receiving optimal DOTMA/E7 also
exhibited a better anti-cancer activity compared to those receiving
CpG/E7 or CFA/E7 formulations.
[0125] 11. Cationic lipids induce ROS production in a dose
dependent manner, resulting in dendritic cell death and reduced
immunostimulatory effect at high doses
[0126] Draining lymph node from mice (n=4 per condition) received
subcutaneous injections of DOTAP/E7 containing 0, 15, 100 or 600
nmols lipid were isolated at 2 h after the injection. Total lymph
node cells were incubated with DCFH-DA compound at 37.degree. C.
for 30 min prior to flow cytometric analysis. Large granular cells
were gated and analyzed for the expression of ROS where the
fluorescent product DCF was generated in the presence of ROS. The
relative percentages of cells with positive ROS signals are listed
in FIG. 10A. Cytotoxicity in the draining lymph node was carried
out by collecting cells at 10 h after DOTAP/E7 injection and
staining with appropriate antibodies. In FIG. 10B, the relative
percentages of dead cells in dendritic cells (DC) are shown in the
line plot (.quadrature.) and the bar chart represents the numbers
of live DC per 10.sup.5 LN cells. The numbers were normalized to
the untreated control and analyzed statistically (**p<0.01).
Cells from mice that received DOTAP 15 nmol exhibited basal level
of ROS production (<5%), whereas cells from mice injected with
DOTAP 100 nmole dose produced relatively higher levels of ROS
(.about.20%). Strikingly, a majority of large granular cells
(.about.80%) from DOTAP 600 nmol group showed positive ROS signal.
At 10 h post subcutaneous injection, total lymph node cells were
harvested and analyzed for cell death by flow cytometry (FIG. 10B).
Percentage of cell death (propidium iodide positive) within the CD
1 lc.sup.+(dendrtitic cell) population increased with lipid dose
and correlated positively with the ROS production shown in FIG.
10A. Percentage of cell death in DC population was about twice as
high for the group injected with DOTAP high dose compared to the
group of untreated control. Also shown in FIG. 10B are the numbers
of live CD11c.sup.+ cells per 10.sup.5 lymph node cells as a
function of the dose of DOTAP lipid. Mice receiving DOTAP/E7 with
lipid at 100 nmol exhibited the highest amount (**p<0.01) of
live dendritic cells among other treatment groups. The draining
lymph node weighed more 2 days after mice received the optimal
formulation. Collectively, the results indicate that ROS production
induced by high dose DOTAP may cause dendritic cell death.
[0127] Further, as illustrated in FIG. 10C, the density of the
cationic charge is important for the immunostimulatory effect and
resulting anti-cancer activity. Both ROS generation and anticancer
activity were diminished by co-formulating high ratios of an inert,
neutral lipid, DOPC with the cationic lipid/E7 complex, resulting
in a decrease of the cationic charge density.
[0128] 12. Lipidation of a peptide antigen results in improved
encapsulation into the cationic lipid/antigen complex
[0129] Cationic lipid/antigen complexes were prepared as described
above. Peptide encapsulation efficiency was determined by the
percentage of the liposome-bound peptide using LavaPep.TM. peptide
quantification kit (commercially available from Fluorotechnics of
Sydney, Australia). Since unincorporated lipopeptide aggregated and
could not pass the exclusion filter, the incorporated lipopeptide
was measured as the amount associated with the extruded liposomes
in the presence of 1% SDS and reported as the mean.+-.SD (n=3). For
water-soluble peptide such as native E7 and KSS-E7, the unbound
peptide was separated from the complex by a Microcon.RTM.
centrifugal filtration device (commercially available from
Millipore of Bedford, Mass.). The concentration of the unbound
peptide was measured using LavaPep.TM. according to the
manufacturer's instruction. The efficiency of encapsulation was
determined as (1-% unbound peptide) and was reported in Table 2 as
the mean.+-.SD (n=3).
TABLE-US-00001 TABLE 2 Composition of the synthetic lipopeptides
and comparison of peptide antigen entrapment efficiency in DOTAP
liposomes at molar ratio lipopeptide: DOTAP = 1:40 Peptide
composition Spacer CTL Entrapment Peptide name Lipid seq. epitope
efficiency (%) Native E7 RAHYNIVTF 27.1 .+-. 5.8% [SEQ. ID. NO. 1]
KSS-E7 KSS RAHYNIVTF 26.4 .+-. 6.1% [SEQ. ID. NO. 1] PA-E7 Palmitic
-- RAHYNIVTF 84.5 .+-. 6.4% [SEQ. ID. NO. 1] .alpha.-PA-KSS-E7
Palmitic KSS RAHYNIVTF 92.8 .+-. 4.2% [SEQ. ID. NO. 1]
.epsilon.-PA-KSS-E7 Palmitic KSS RAHYNIVTF 94.1 .+-. 4.6% [SEQ. ID.
NO. 1]
[0130] 13. Anti-tumor efficacy of the cationic lipid/antigen
complex improves with antigen encapsulation efficiency
[0131] TC-1 tumor bearing mice (8-12 per group) were given a
single-dose treatment on day 6 (after establishment of the tumor)
with DOTAP/E7 (containing 10 nmol or 5 nmol peptide) or
DOTAP/E7-lipopeptide formulations (containing 5 nmol of peptide
antigen). Compositions of 100 nmole of cationic lipid were used in
each case. DOTAP/E7 with 5 nmol of peptide did not show a
significant anti-tumor activity. On the contrary, both of the
E7-lipopeptides (a or c position) at 5 nmol of antigen, when
formulated in DOTAP liposomes, showed a significant enhanced
therapeutic effect (**p<0.01) compared to DOTAP with the native
E7 antigen at 5 nmol (FIG. 11). The anti-tumor activity elicited by
the lipopeptides was similar to that of DOTAP/E7 with 10 nmol.
PA-E7, which is a palmitoylated E7 peptide (without KSS spacer),
when formulated in DOTAP liposome failed to show an enhanced
anti-tumor activity as seen in other lipopeptide formulations,
likely owing to the epitope being hidden by directly attaching a
fatty acid to the peptide. Anti tumor activity is enhanced with
DOTAP/E7-lipopeptide due, at least in part, to increased
encapsulation efficiency of the antigen. This demonstrates that by
increasing the hydrophobicity of the antigen, incorporation into
the complex is increased resulting in an increased antigen-specific
immune response. Mice treated with dextrose (5%) were used as a
negative control.
[0132] 14. Cationic lipid/lipidated antigen complex increases
antigen specific CTL response.
[0133] Immunization with DOT AP/E7-lipopeptide increased the
production of IFN-.gamma. secreting CD8.sup.+ T cells. Mice were
injected with the various formulations and seven days after the
last immunization, spleen cells from immunized mice were isolated.
The cells were stimulated in vitro with or without E7 peptide (5
.mu.g/ml) for 6 h, and were stained with a surface CD8 marker and
an intracellular IFN-.gamma. cytokine prior to FACS analysis. The
percentage of CD8.sup.+ IFN-.gamma..sup.+ double positive cells per
10.sup.4 total CD8.sup.+ from each treatment group were shown in
FIG. 12 as mean.+-.SD and were statistically analyzed by paired
t-test (**p<0.01, n=4).
[0134] To assess the epitope-specific immune response induced by
DOTAP/E7-lipopeptide vaccination, IFN-.gamma. producing CD8.sup.+ T
cells were analyzed. Spleen cells from control or immunized mice
were isolated at one week after the final immunization and were
stimulated with 5 .mu.g/ml E7 peptide or without peptide followed
by intracellular staining for IFN-.gamma.. As described in Table 2
(above) and depicted in FIG. 12, antigen incorporation into the
complex was significantly improved in the case of the lipopetide
antigen, and the number of IFN-.gamma. producing CD8.sup.+ cells
were therefore significantly higher in the mice that received 5
nmol of .epsilon.-PA-KSS-E7 formulated in the DOTAP liposomes than
those of both 10 and 5 nmols of the native E7 (**p<0.01). Again,
KSS-E7 showed a superior result than the native E7 at the equal
antigen amount. The IFN-.gamma. production by the CD8+ cells was
E7-specific, as the unpulsed cells showed only background level of
the cytokine. These results showed that incorporation of
E7-lipopeptides with increased hydrophobicity and complexation
efficiency into DOTAP liposomes clearly enhanced efficacy of the
cationic lipid/antigen complex and increased the amount of
IFN-.gamma. producing CD8.sup.+ T lymphocytes in the lymphoid
organ.
[0135] 15. Antigenicity of the peptide antigen is improved by the
attachment of a short amino acid sequence unrelated to sequences
existing in the parent peptide sequence, leading to improved
anti-tumor efficacy of a lipid/antigen complex consisting of DOTAP
and KSS-E7 peptide
[0136] The KSS (lysine-serine-serine)-E7 peptide without the lipid
chain attached, when formulated in DOTAP cationic lipid, provided a
much stronger immune response than the native E7 peptide formulated
in the DOTAP complex (FIGS. 11 and 12), despite comparable
encapsulation efficiency to that of the native E7 (Table 2). It is
known that the capacity of a peptide to bind and stabilize MHC
class I molecules can be directly correlated with its ability to
induce specific CTL responses [Feltkamp, M. C. et al, Vaccination
with cytotoxic T lymphocyte epitope-containing peptide protects
against a tumor induced by human papillomavirus type 16-transformed
cells. Eur J Immunol, 23, (9), 2242-2249 (1993)]. We evaluated the
MHC class I binding affinity of native and KSS-elongated E7
peptides. RMA-S cells, a mouse lymphoma cell line at a
concentration of 5.times.10.sup.5 cells/ml were incubated overnight
at 27.degree. C. with native E7 or KSS-E7 peptide (10 .mu.M). Cells
incubated with medium were used as a control. Cells were then
incubated for 2 h at 37.degree. C. After washes, cells were stained
with fluorescently conjugated monoclonal antibodies against
H-2D.sup.b or H-2K.sup.b molecules on the cell surface prior to
flow cytometry analysis. E7 peptide (a.a. 49-57) is a known epitope
restricted to H-2D.sup.b and it caused a four-fold up-regulation of
H-2D.sup.b molecules on RMA-S cells compared to the control (FIG.
13). An 8-fold increase in the mean fluorescence was observed for
KSS-E7 peptide. No up-regulation of H-2K.sup.b molecules was
detected on RMA-S cells after incubating with either E7 or KSS-E7
peptide. The results demonstrate that KSS-E7 has an improved
binding affinity to H-2D.sup.b molecules than the native E7
peptide, which led to a superior anti-tumor activity when
formulated in the DOTAP/antigen complex.
[0137] The study demonstrates that the immunogenicity of an
immunogenic peptide can be improved or altered by attaching a short
sequence of amino acids unrelated to the natural parent protein
sequence from which the immunogenic peptide is derived.
[0138] 16. The effect of ionic interaction between the cationic
lipid and antigen on the efficiency of antigen incorporation into
the cationic lipid/antigen complexes
[0139] For these studies DOTAP was solublized in chloroform and dry
films prepared from 7 mg of DOTAP in 16.times.100 mm glass tubes.
After drying under vacuum the liposomes were hydrated with 0.5 ml
of the antigen (HPV-16 E7, amino acids 11-20, YMLDLQPETT (SEQ. ID.
NO. 2) in (1) a high ionic strength environment (15 mM sodium
phosphate, 150 mM NaCl, pH 7.0), or (2) a low ionic strength
environment (0,5 ml of the antigen in 15 mM sodium phosphate, 50 mM
NaCl pH 7.0). Particle size was 100 nm.
[0140] Antigen encapsulation efficiency was analyzed by filtering
the particles over a 100K Nanosep microfilter (commercially
available from Pall Corp. of Ann Arbor, Mich.), for 20 minutes at
5000 rpm in a microfuge. The concentration of antigen in the
starting buffer and in the flow-through from the Nanosep filters
(unbound peptide) was analyzed by reverse phase chromatography to
determine percent encapsulation. Encapsulation efficiency was
calculated as (1-% unincorporated peptide) as seen in Table 3.
TABLE-US-00002 TABLE 3 Ecapsulation of antigen into cationic
lipid/antigen complex is enhanced by increasing the negative charge
on the antigen. Formulation Buffer Percent Encapsulation High ionic
strength environment 20 mM 22% Sodium Phosphate 150 mM NaCl, pH 7.0
Low ionic strength environment 20 mM 50% Sodium Phosphate 50 mM
NaCl, pH 7.0
[0141] Ionic interactions are minimized in high ionic strength
environment. Higher strength ionic environments effectively
decrease the negative by increasing the ionic strength of the
formulation buffer (150 mM NaCl), ionic interactions between the
negatively charged antigen and the positively charged lipid were
minimized resulting in reduced encapsulation. By reducing ionic
strength, ionic interactions between the lipid and antigen were
enhanced leading to greater incorporation of the antigen into the
complex. Incorporation efficiency into the cationic lipid/antigen
complex can therefore be enhanced by manipulating the antigen to
increase the negative charge by altering the formulation buffer or
by attaching an anionic or poly-anionic compound to the
antigen.
[0142] Discussion
[0143] As described in U.S. Pat. No. 7,303,881, a broad class of
cationic lipids can act as potent immunostimulators together with
an antigen to generate antigen specific immune responses in the
treatment of disease. For example, U.S. Pat. No. 7,303,881
discloses that liposomes comprised of cationic lipids activate
dendritic cells as demonstrated by the stimulation by cationic
lipids of the expression of costimulatory molecules CD80/CD86 on
DC2.4 dendritic cells (FIGS. 14A and 14B). As shown in FIG. 14A,
the ability to stimulate the expression of CD80/CD86 on DC2.4 cells
by different cationic liposomes varies greatly.
Lipofectamine..RTM.., a 3:1 (w/w) liposome formulation of the
polycationic lipid
2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanamini-
-um trifluoroacetate (DOSPA) and the neutral lipid dioleoyl
phosphatidylethanolamine (DOPE), and liposomes prepared from
0,0'-dimyristyl-N-lysyl aspartate (DMKE) and
0,0'-dimyristyl-N-lysyl-glutamate (DMKD), strongly stimulated the
expression of CD80/CD86 by CD2.4 cells.
[0144] The ability of different cationic lipids to stimulate the
expression of CD 80 on DC 2.4 cells varied. Both hydrophilic head
and the lipophilic tail of the lipids have significant effect on
this ability. For example, the DXEPC lipids with the ethyl
phosphocholine (EPC) head groups appear, in general, to be more
potent than the DXTAP lipids with trimethylammonium propane (TAP)
head group. Within the lipids bearing one particular head group
structure, lipids with shorter
(1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLEPC-12:0),
1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC-14:0)) or
unsaturated (1,2-dioleoyl-sn-glyccro-3-ethylphosphocholine
(DOEPC-18:1)) acyl chains appear to be more potent than those with
longer (1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine
(DPEPC-16:0)) or saturated
(1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSEPC-16:0)) acyl
chains (FIG. 14B). These data demonstrated that multiple cationic
lipids were capable of stimulating the activation of dendritic
cells. Three representative cationic lipids DOTAP, DOTMA, and DOEPC
were therefore selected for additional studies to determine the
mechanism by which cationic lipids act as immune stimulators. The
data presented herein with the representative cationic lipids may
be extrapolated to other cationic lipids that stimulate immune
responses.
[0145] Data from the present studies have led to the observation
that the cationic lipids are not only efficient targeting and
delivery vehicles for antigens to APC of the immune system, but
also function as potent adjuvants under low dose composition ranges
to directly influence immune system function through activation of
MAP kinase dependent signaling pathways with resultant production
of immune system regulatory molecules including cytokines and
chemokines. A clear dose-response effect of cationic lipid on the
immunostimulatory capabilities of the formulations have been
demonstrated. To this end, we have demonstrated that when an
antigen, such as, for example, a peptide epitope of E7 protein of
the HPV type 16, is encapsulated in the cationic liposomes of
either DOTAP, DOTMA or DOEPC (DOTAP/E7, DOTMA/E7 or DOEPC/E7) and
the antigen/lipid complex is administrated at about 100 nmole dose
compositions by a single subcutaneous injection, it induces
regression of the HPV 16 E7-positive tumor, TC-1, in mice. Upon
receiving the lipid/antigen complex, the particles were mainly
taken up by dendritic cells, the major professional antigen
presenting cells. The initiation of dendritic cell activation and
migration to the draining lymph node facilitates immune responses
against antigen specific TC-1 tumors as demonstrated. Functional
CD8.sup.+ T lymphocytes were generated in mice upon receiving a
DOTAP/E7 injection and tumor sizes decreased and exhibited enhanced
apoptosis, owing to the increasing number of infiltrating T cells
in the tumor microenvironment. The resulting bell-shaped (activity
decreases above and below the optimal dose) cationic lipid dose
response curve demonstrates activity at very low doses, indicating
that the activity of the cationic lipids as adjuvants or
immunostimulators is so potent that the EC50 is as low as about 15
nmol per injection. High doses of cationic lipids eliminate the
immunostimulatory activity. We have also demonstrated that when an
antigen such as, for example, ovalbumin, is incorporated into the
cationic liposomes and administered in a single subcutaneous
injection, effective antibodies against the antigen are produced.
It is clear that at optimal dose compositions, the cationic lipids
and cationic lipid/antigen complexes provide simple, safe, and very
efficient immunotherapies useful in preventing and treating
diseases.
[0146] T regulatory cells were initially described by Gershon et
al. [Eardley, D D, et al., Immunoregulatory circuits among T-cell
sets. I T-helper cells induce other T-cell sets to exert feedback
inhibition. J Exp Med 147:1106; and Cantor, H, et al.,
Immunoregulatory circuits among T-cell sets. II. Physiologic role
of feedback inhibition in vivo: absence in NZB mice. J Exp Med
147:1116 (1978)] in the 1970s and were called suppressive T cells.
Recent studies have explored the role of CD4+ CD25+regulatory T
cells (T-reg) in the suppression of tumor immunity in several
murine models as well as in cancer patients [Comes, A, et al.,
CD25+ regulatory T cell depletion augments immunotherapy of
micrometastases by an IL-21-secreting cellular vaccine. J Immunol
176:1750 (2006)]. The frequency of T-reg cell population increases
in the peripheral blood of cancer patients [Sasada, T, et al.,
CD4+CD25+regulatory T cells in patients with gastrointestinal
malignancies: possible involvement of regulatory T cells in disease
progression. Cancer 98:1089 (2003)]. They are also enriched among
the tumor infiltrating lymphocytes and in the draining lymph nodes
[Baecher-Allan, C, and Hafler, D A, Suppressor T cells in human
diseases. J Exp Med 200:273 (2004)]. Also, accumulation of T-reg in
tumor-associated tissue predicts poor prognosis or survival
[Baecher-Allan, C, and Anderson, D E Immune regulation in
tumor-bearing hosts. Curr Opin Immunol 18:214 (2006)]. Although the
detailed mechanism of how T-reg dampens normal T-cell immunity is
not well understood, it has been reported that the anti-tumor
activity is enhanced by using anti-CD25 antibody to block T-reg
cells [Attia, P, et al., Inability of a fusion protein ofIL-2 and
diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK)to
eliminate regulatory T lymphocytes in patients with melanoma. J
Immunother 28:582 (2005)]. Indeed, it has become apparent that it
will be necessary to monitor and characterize both the effector and
T-reg responses in patients that receive candidate human tumor
vaccines [Baecher-Allan, C, and Anderson, D E Immune regulation in
tumor-bearing hosts. Curr Opin Immunol 18:214 (2006)]. In the
present studies, we found a clear correlation of the anti-tumor
activity of the DOTAP/E7 with the reduction of T-reg cells.
[0147] Cationic lipids therefore constitute a novel class of
immune-stimulators that at specific doses can be applied
effectively in modulating the body's immune response and in the
development of therapeutic agents and vaccines for both
prophylactic and therapeutic use.
[0148] It has been known for several years that proteins and
peptides have significant potential for use in the development of
immuno-therapies and vaccines. A major drawback to the successful
development of such therapies has been inefficient delivery of the
antigens to the immune system. Also, intensive efforts have been
undertaken to develop safe and potent immune stimulants for use in
infectious diseases and as therapies for cancer. Current
technologies involving adjuvants such as Montanide ISA.TM. 51 and
720 from SEPPIC, Inc., which is a mixture of a surfactant from the
mannide monooleate family with a mineral oil or nonmineral oil,
respectively, have been tested in vaccines for infectious diseases
and cancer in humans [Aucouturier, J, et al., Montanide ISA 720 and
51: a new generation of water in oil emulsions as adjuvants for
human vaccines. Expert Rev Vaccines 1:111 (2002)]. Various studies
demonstrate the ability of Montanide ISA.TM. 51 and 720 to enhance
antibody titers and also specific CTL response [Yamshchikov, G V,
et al., Evaluation of peptide vaccine immunogenicity in draining
lymph nodes and peripheral blood of melanoma patients. Int J Cancer
92:703 (2001)]. However, this type of water-in-oil adjuvant
requires a critical step of emulsification during the manufacturing
process, which is not always easy to control. More importantly, a
phase I clinical trial of a multi-epitope polypeptide TAB9 combined
with Montanide ISA 720 indicated that seven out of eight volunteers
from the lower dose group showed moderate or severe local
inflammation, while four out of eight subjects from the higher dose
group developed granulomas and sterile abscesses [Toledo, H, et
al., A phase 1 clinical trial of a multi-epitope polypeptide TAB9
combined with Montanide ISA 720 adjuvant in non-HIV-1 infected
human volunteers. Vaccine 19:4328 (2001)]. ISA 720 is composed of
metabolizable oil and is supposed to be less reactogenic in humans.
However, like most other adjuvants, the surfactant in the emulsion
may trigger toll-like receptors (TLR) on dendritic cells and
macrophages thus inducing the production of NF-KB and inflammatory
responses [Aucouturier, J, et al., Montanide ISA 720 and 51: a new
generation of water in oil emulsions as adjuvants for human
vaccines. Expert Rev Vaccines 1:111 (2002)].
[0149] We have demonstrated that the cationic lipids do not enhance
the expression of NF-KB, suggesting that dendritic cells
stimulation by cationic lipids is signaled through an NF-KB
independent mechanism [Cui, Z., et al (2005). Immunostimulation
mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm 2:
22-28)]. Thus, cationic liposomes could belong to a unique class of
adjuvant with an improved safety profile.
[0150] We have also demonstrated that by lipidating an antigen such
as, for example, linking a mono-palmitic acid to a KSS-elongated E7
peptide (at either .alpha. or .epsilon. position), the peptide
encapsulation efficiency within the cationic liposome/antigen
complex can be improved over that of the water-soluble antigen. The
DOTAP/E7-lipopeptide complex, which consists of only two molecules,
induced an overall enhancement in generating antigen-specific CTL
for eradicating HPV positive TC-1 cells. The cationic lipid
composition was maintained at 100 nm. When the antigen was
administered at a reduced dose (5 nmol or less) to tumor bearing
mice, the DOTAP/E7-lipopeptide complex exhibited a superior
anti-tumor activity compared to the original DOTAP/E7 formulation
at a full dose (10 nmol). The enhanced antigenicity and anti-tumor
activity of the lipopeptide was correlated with the enhanced
encapsulation of the lipopeptide in the liposomes. As shown in
Table 2, the entrapment efficiency of lipopeptide was 90% at a
peptide loading of 2.5 mol % total lipid, whereas only about 25% of
the native water soluble E7 peptide only got incorporated into the
complex. Similar enhanced liposome encapsulation of lipopeptides
has also been reported [Yagi, N. et al., Preparation of functional
liposomes with peptide ligands and their binding to cell membranes.
Lipids, 35, 673-680 (2000); and Liang, M. T. et al., Encapsulation
of lipopeptides within liposomes: effect of number of lipid chains,
chain length and method of liposome preparation. Int J Pharm, 301,
247-254 (2005)]. In order for the peptide to be presented by the
MEW class I pathway, the peptide has to enter the cytoplasm of the
APC. Cationic liposomes deliver the encapsulated, but not free,
peptide into the cells. Thus, with higher the encapsulation of the
peptide, better delivery and antigenicity can be expected. In
addition, under dosing conditions as demonstrated, the cationic
lipid also acts as a potent immunostimulator leading to a strong
antigen-specific immune response resulting in the observed tumor
cell death.
[0151] The importance of ROS has been implicated in innate immune
response and T cell activation [Kantengwa et al, Superoxide anions
induce the maturation of human dendritic cells. Am J Respir Crit,
Care Med 167:431-437 (2003)], and high ROS production leads to cell
death [Tobiume K, et al, AS K1 is required for sustained
activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep
2:222-228 (2001)], [Aramaki Y, et al, Induction of apoptosis in
WEHI231 cells by cationic liposomes. Pharm Res17:515-520 (2000)].
We demonstrated that ROS was induced by the cationic lipid in cells
in the draining lymph node and a high dose of DOTAP lipid led to
killing of dendtritic cells. Indeed, Iwaoka et al. have shown that
cationic liposomes can induce ROS in macrophages in vitro [Iwaoka
S, et al, Cationic liposomes induce apoptosis through p38 MAP
kinasecaspase-8-Bid pathway in macrophage-like RA W264.7 cells. J
Leukoc Biol 79:184-191 (2006)]. Data shown in FIG. 10A clearly
demonstrate that cationic lipids are capable of generating ROS in
vivo in the draining lymph node after subcutaneous injection of
DOTAP/E7 complexes. The same data also suggest that excess ROS
generated by a high dose of cationic lipid leads to enhanced
dendritic cell death. These data support administering to a subject
a cationic lipid in a dose sufficient to induce the production of
ROS in cells of an immune system of the subject wherein the induced
ROS level is sufficient to increase the immune response above the
immune response present in the absence of the cationic lipid. There
might be other possible reasons related to the loss of
immunostimulation and resulting anticancer activity due to the high
DOTAP dose of the DOTAP/E7 complex. However, the decreased amount
of activated APC in the DLN should definitely play an important
role in the observed decrease in the lymphocyte infiltration (FIG.
3), antigen-specific CTL activities and IFN-.gamma. production
(FIGS. 2 and 8) and, most importantly, the anti-tumor activity
(FIG. 6) at the high vaccine dose. On the other hand, a desirable
level of ROS production is required since DOTAP-induced ROS is
probably the initial signal to mediate the subsequent signal
transduction, such as the ERK and p38 MAP kinases, necessary for
vaccine activity as discussed below in Example 2. Further, we have
demonstrated the importance of the density of the cationic charge
to the immunostimulatory effect and resulting anti-cancer activity
in FIG. 10C. Here it is demonstrated that both ROS generation and
anticancer activity can be diminished by co-formulating high ratios
of an inert, neutral lipid, DOPC with the cationic lipid/E7
complex, resulting in a decrease of the cationic charge
density.
[0152] Example 1 demonstrates the importance of the cationic lipid
dose in the immunostimulatory effect and also highlights the role
of cationic lipid/antigen complexes in the development of simple
and safe immunotherapies to generate strong antigen-specific immune
responses for the treatment of cancer and multiple diseases such as
bacterial and viral infections.
Example 2
[0153] Mechanism of the Immunostimulatory Activity of Cationic
Lipids: Phosphorylation of a Map Kinase, ERK and Induction of
Chemokines
[0154] A. MATERIALS AND METHODS
[0155] 1. Cell Lines and Peptides
[0156] TC-1 cells were provided by TC Wu (Johns Hopkins University,
Baltimore, Md.). These cells are C57BL/6 mouse lung endothelial
cells that have been transformed with the HPV16 E6 and E7 oncogenes
and activated H-ras. Cells were grown in RPMI medium (commercially
available from Invitrogen of Carlsbad, Calif.) supplemented with
10% fetal bovine serum and 100 U/ml penicillin, and 100 mg/ml
streptomycin. The MHC class I restricted peptide from the HPV 16 E7
protein (amino acid 49 to 57, RAHYNIVTF [SEQ. ID. NO. 1]) was
synthesized by the University of Pittsburgh Peptide Synthesis
Facility by solid state synthesis using an Advanced ChemTech model
200 peptide synthesizer and purified by HPLC. [as described in
Feltkamp, et al. Eur J Immunol 23, 2242-2249 (1993)]. Mouse
monoclonal antibodies specific to pERK and ERK2 and siRNA were
purchased from Santa Cruz Biotechnology, Inc. of Santa Cruz, Calif.
Rabbit polyclonal antibody specific to phosphorylated p38 (p-p38)
was obtained from Cell Signaling Technology Inc. of Danvers, Mass.
GeneChip Mouse Genome 430 2.0 Array was obtained from Affymetrix,
Inc. PD-98059, U-0126, PP2, wortmannin, and GF109203X were obtained
from Calbiochem. Pertussis toxin and other reagents were obtained
from Sigma.
[0157] 2. Preparation of Lipid/antigen complexes and determination
of physical properties
[0158] All lipids were purchased from Avanti Polar Lipids
(Alabaster Ala.). Small unilamellar DOTAP, DOEPC, and DOTMA
liposomes were prepared by thin film hydration followed by
extrusion. The lipid, with or without a drug, in chloroform was
dried as a thin layer under a stream of nitrogen in a glass tube.
The thin film was vacuum desiccated for 2-3 h and then re-hydrated
in cell culture grade water (commercially available from Cambrex of
Walkersville, Md.) or buffer containing E7 peptide to a final
concentration of 0.7 mg lipids and 0.1 mg E7 per mL (molar ratio=l
1:1). The lipid dispersion was sequentially extruded through
polycarbonate membranes with pore size of 0.4, 0.2 and 0.1 pm. The
un-entrapped peptide was not removed. The liposomes were stored at
4.degree. C. until use. E7 peptide association with the liposome
was determined by measuring the percentage of liposome-bound
peptide. In brief, unbound E7 peptide from DOTAP/E7 or
DOTAP/E7/drug (MAP kinase inhibitor) complexes was separated by a
Microcon .sup.R centrifugal filtrate devices (Millipore, Bedford,
Mass.) and the concentration of unbound peptide was measured by
Micro BCTM Protein Assay Kit (Pierce, Rockford, Ill. The efficiency
of peptide association was determined as percent unbound peptide.
Approximately 30% of E7 peptide was associated with the
liposomes.
[0159] 3. Statistical analysis.
[0160] Data are presented as mean.+-.SD of at least 3 independent
experiments. Two-tailed Student's t tests were used to assess
statistical significance for differences in means. Significance was
set at p<0.05.
[0161] 4. RNA extraction and Microarray
[0162] RNA was extracted by RNeasy Mini Kit from Qiagen of
Germantown, Md., according to the manufacturer's instructions.
Seven .mu.g of total RNA was used to synthesize cDNA. A custom cDNA
kit from Life Technologies of Gaithersburg, Md., was used with a
T7-(dT)24 primer (SEQ ID NO: 10) for this reaction. Biotinylated
cRNA was then generated from the cDNA reaction using the BioArray
High Yield RNA Transcript Kit. The cRNA was then fragmented in
fragmentation buffer (5.times. fragmentation buffer; 200 mM
Tris-acetate, pH8.1, 500 mM KOAc, 150 mM MgOAc) at 94.degree. C.
for 35 minutes before the chip hybridization. Fifteen 1 .mu.g of
fragmented cRNA was then added to a hybridization cocktail
(0.05.mu.g/.mu.l fragmented cRNA, 50 .mu.M control oligonucleotide
B2, BioB, BioC, BioD, and cre hybridization controls, 0.1 mg/ml
herring sperm DNA, 0.5 mg/ml acetylated BSA, 100 mM MES, IM NaCl,
20 mM EDTA, 0.01% Tween 20). Ten .mu.g of cRNA was used for
hybridization. Arrays were hybridized for 16 h at 45.degree. C. in
the GeneChip Hybridization Oven 640. The arrays were washed and
stained with R-phycoerythrin streptavidin in the GeneChip Fluidics
Station 400. After this, the arrays were scanned with the Hewlett
Packard GeneArray Scanner. Affymetrix GeneChip Microarray Suite 5.0
software was used for washing, scanning, and basic analysis. Sample
quality was assessed by examination of 3' to 5' intensity ratios of
certain genes.
[0163] 5. Bone Marrow-Derived Dendritic Cells (BMDC)
[0164] BMDC were generated using a procedure modified from that
described in Inaba K., et al., Generation of large numbers of
dendritic cells from mouse bone marrow cultures supplemented with
granulocyte/macrophage colony-stimulating factor. J Exp Med
176:1693-702, (1992). Briefly, bone marrow was harvested from the
femurs and tibias of C57BL/6 female mice. After red blood cell
lysis, plastic adherence allowed the separation of dendritic cell
precursors from lymphocytes. The remaining bone marrow cells were
cultured for 6 days in RPMI1640 medium supplemented with 10% FBS,
non-essential amino acids, antibiotic/antimycotic and GM-CSF and
1L-4 (R&D systems) at 1,000 U/ml each. The medium was changed
every other day. Cells were used in assays on day 6. These cells
were >90% dendtritic cells, as verified by flow cytometry for
CD11c expression.
[0165] 6. RT-PCR
[0166] Total RNA was isolated from BMDC by Rneasy Mini Kit from
Qiagen according to the manufacturer's instruction. Following
digestion with Dnase for 30 min at 37.degree. C., the total RNA
concentration was determined by spectrophotometry. Primer pairs for
mouse CCL2, CCL3, CCL4 and .beta.-actin (forward primer
5'-AAGCCAGCTCTCTCTTCCTC-3' [SEQ. ID. NO. 3] and reverse primer
5'-CCTCTCTCTTTGAGCTTGGTG-3' [SEQ. ID. NO. 4] for CCL2; forward
primer 5'-ATCATGAAGGTCTCCACCAC-3' [SEQ. ID. NO. 5] and reverse
primer 5'-TCTCAGGCATTCAGTTCCAG-3' [SEQ. ID. NO. 6] for CCL3;
forward primer 5'-GCTCTGTGCAAACCTAACCC-3' [SEQ. ID. NO. 7] and
reverse primer 5'-TGTGATGGTGGGAATGGGTCAG-3' [SEQ. ID. NO. 8] and
reverse primer 5'-TTTGATGTCACGCACGATTTCC-3' [SEQ. ID. NO. 9] for
.beta.-actin [Wang H., et al., Potential involvement of monocyte
chemoattractant protein (MCP)-1/CCL2 in IL-4-mediated tumor
immunity through inducing dendritic cell migration into the
draining lymph nodes, Int Immunopharmacol 3:627-42, (2003)] were
synthesized by IDT technology. RT-PCR was performed using the
one-step RT-PCR kit (commercially available from Invitrogen of
Carlsbad, Calif) where reverse transcription and DNA amplification
occur in the same reaction. Briefly, 1 .mu.g of total RNA was used
as a template in a reaction that included the appropriate primers
in the presence of both reverse transcriptase and Taq polymerase.
The mixture was incubated at 45.degree. C. for 30 min and cycled 25
times at 94.degree. C. for 30s, 55.degree. C., for 30s, and
72.degree. C. for 2 min. Appropriate negative controls of
amplification included reactions without reverse transcriptase. PCR
products were visualized by UV transillumination of 1.5% agarose
gels stained with ethidium bromide.
[0167] 7. CCL2 production by lymph node cells and BMDC after DOTAP
stimulation
[0168] Two days after C57BL/6 female mice (n=5) received
subcutaneous injections of PBS, DOTAP/E7 or DOTAP/E7/MAP Kinase
Inhibitor, the amount of CCL2 production within the draining lymph
nodes was analyzed by CCL2 ELISA kit (commercially available from
BD Biosciences). BMDC from C57BL/6 mice were cultured for six days
in the presence of recombinant mGM-CSF and mIL-4 as described. At
day 6, BMDC (10.sup.6 cells in 1 mL/well) were stimulated with
medium control or liposomes for 1 h, 24 h or 48 h at 37.degree. C.
For inhibitor treatment, the inhibitors were pre-incubated with
BMDC for 20 min before liposome stimulation. The CCL2 production in
supernatant was analyzed by CCL2 ELISA kit.
[0169] 8. CCL2 Immunohistochemical Staining
[0170] The draining lymph nodes of mice were removed at day 2,
embedded in OCT compound, snap frozen in liquid nitrogen, and
stored at -80.degree. C. until used for immunohistochemical
analysis. The goat ABC Staining System (commercially available from
Santa Cruz Biotechnology Inc. of Santa Cruz, Calif.) was used
according to the manufacturer's protocol. Briefly, 8 .mu.m thick
crystostat sections of draining lymph nodes were cut and fixed in
cold acetone for 10 min and washed in PBS 3 times for 5 min each
wash. The sections were then sequentially incubated in 1% hydrogen
peroxide (in H.sub.2O) for 10 min to block endogenous peroxidases,
in 1.5% blocking serum (donkey serum) in PBS for 60 min, then with
the primary antibody (1:100 dilution; commercially available from
Santa Cruz Biotechnology Inc. of Santa Cruz, Calif.) overnight at
4.degree. C. The slides were then incubated with biotinylated
secondary antibody (1:150 dilution; commercially available from
Santa Cruz Biotechnology Inc. of Santa Cruz, Calif.) with AB enzyme
reagent for 30 min and incubated in 3 drops peroxidase substrate
for 10 min or longer.
[0171] 9. Western Blot Analysis
[0172] BMDC cell lysate was collected after different treatments
and total cellular protein was resolved on polyacrylamide/SDS gels
and then transferred to polyvinylidene difluoride membranes. The
membranes were blocked with 5% nonfat milk in Tris-buffered saline
for 1 h and then incubated from 1 h to overnight with primary
antibody. After washing the membranes with Tris-buffered saline
three times, the membranes were incubated horseradish peroxidase
conjugated secondary antibody for 1 h. The peroxidase activity
associated with the protein bands was detected by enhanced
chemiluminescence using ECL plus (Amershan International) followed
by autoradiography.
[0173] 10. siRNA Treatment
[0174] RNA interference experiments were performed with siRNA for
ERK 1 and control siRNA (commercially available from Santa Cruz
Biotechnology of Santa Cruz, Calif.) using Lipofectamine 2000
reagent (commercially available from Invitrogen of Carlsbad,
Calif), according to the manufacturer's instructions. Briefly, on
day 5, BMDC were seeded at 5.times.10.sup.5 per well in 12 well
plates and transfected immediately with 80 nM siRNA using 4 .mu.l
transfection reagent. The cells were incubated with DOTAP or LPS
for another 16 h. The supernatant was analyzed by ELISA for
CCL2.
[0175] B. RESULTS
[0176] A transformed dendritic cell line, DC2.4, which has been
shown to be a good model for APC [Mendoza L., et al., Prophylactic,
therapeutic and anti-metastatic effects of BMDC and DC lines in
mice carrying HPV 16-associated tumours, Int J Oncol 23:243-7,
(2003); Okada N., et al., Effects of lipofectin-antigen complexes
on major histocompatibility complex class I-restricted antigen
presentation pathway in murine dendriticcells and on dendritic cell
maturation, Biochim Biophys Acta 1527:97-101, (2001)], was used to
study global gene regulation induced by DOTAP by using the
Affymetrix microarray analysis (FIG. 15A). The data showed that
DOTAP induced overexpression of several chemokines, including
monocyte chemoattractant protein-1 ("MCP-1")/CC chemokine-2
("CCL2"), macrophage inflammatory protein-1 alpha
("MIP-1.alpha.")/CC chemokine-3 ("CCL3"), macrophage inflammatory
protein-1 beta (MIP-1(3)/CC chemokine-4 ("CCL4"). Besides CC
chemokine induction, the IL-1 signal was down-regulated, because
IL-1 .beta. was decreased and IL-1 receptor antagonist ("IL1RA")
was increased upon 50 .mu.M DOTAP treatment for 16 h.
Interestingly, the dendritic cell marker, CD11c, was induced by the
DOTAP liposomes, suggesting that the cationic lipids play a role in
dendritic cell maturation. The induction of chemokine mRNA was
confirmed by RT-PCR with murine BMDC (FIG. 15B).
[0177] As mentioned previously, chemokines are involved in
lymphocyte migration and play important roles in the immune
response. Chemokine induction may explain the major adjuvant
activity of cationic liposomes as mentioned previously. This
hypothesis prompted us to further study the detailed mechanisms
underlying the process. Liposomes prepared from different lipids
were utilized to determine if the induction of chemokines is a
general phenomenon by liposomes. Using BMDC, the results showed
that only the quaternary cationic liposomes (DOTAP and DOEPC)
induced the MCP-1/CCL2 release from BMDC. Neutral (DOPC and DOG)
and negatively charged (DOPS and DOPG) liposomes did not (FIG.
165). Also a tertiary amine analog of DOTAP, DODAP, did not induce
the activity either, suggesting that the activity requires a
quaternary amino head group in the lipid. LPS was also included in
the experiments as a positive control. FIG. 16 also shows that the
CCL2 induction by cationic liposomes reaches a maximum amount in 24
h, because 48 h incubation did not result in higher levels of
chemokine production. Our data also show that DOTAP--induced CCL2
expression is dose-dependent (FIG. 17). Five .mu.M DOTAP induced
significant amounts of CCL2 from BMDC and maximum induction was
reached at 45-75 .mu.M. To identify which pathway was involved in
the CCL2 induction by DOTAP in BMDC, several inhibitors specific to
distinct signaling pathways were used. PD98059 ("PD") and U-0126
("U"), specific inhibitors for the ERK pathway, almost completely
abolished CCL2 production, but surprisingly, SB203586 ("SB"), an
inhibitor of the p38 pathway, synergistically increased CCL2
production induced by DOTAP (FIG. 18). Our data also clearly showed
that PKC pathway and Src kinase are not involved in the CCL2
production induced by DOTAP, because the PKC inhibitor GF109203X
("GF") and the Src kinase inhibitor PP2 had no inhibitory effect.
FIG. 18 also indicates that PI-3 kinase and Gi-dependent
G-protein-coupled-receptor (GPCR) were likely involved in the CCL2
release upon DOTAP treatment, because wortmannin ("Wort") and
pertussis toxin ("PTx") had some inhibitory effect.
[0178] It is known that some chemokines are regulated by the ERK
pathway [Yoo J. K., et al., IL.-18 induces monocyte chemotactic
protein-1 production in macrophages through the
phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2pathways, J Immunol
175:8280-6, (2005)], and verified in our system. Using BMDC to
study activation of the ERK pathway, our data showed that DOTAP
induced ERK phosphorylation within 10 min of exposure and
phospho-ERK (.sub.PERK) stayed at a high level for at least 40 min
(FIG. 19A). In addition, p38 was also slightly activated by DOTAP.
However, no phosphorylation of IKB and subsequent degradation were
detected following DOTAP incubation (data not shown), suggesting
that the NF-KB was not involved in the signal transduction
initiated by DOTAP, consistent with our previous findings [Cui Z.,
et al., Immunostimulation mechanism of LPD nanoparticle as a
vaccine carrier, Mol Pharm 2:22-8, (2005)]. Western blotting showed
that inhibition of p38 could also synergistically increase the ERK
phosphorylation triggered by DOTAP, suggesting that the ERK pathway
and p38 are regulated reciprocally (FIG. 19B). In other words,
activation of p38 may inhibit the activation of ERK. Consistent
with the ELISA data in FIG. 18, our data have also shown that
DOTAP-induced activation of ERK is mediated by PI-3 kinase because
wortmannin inhibited ERK phosphorylation induced by DOTAP. However,
PTx, the Gi inhibitor, only showed slight inhibitory effect on the
DOTAP--induced ERK phosphorylation (FIG. 19C). On the other hand,
the PKC pathway and Src kinase are not involved in this process,
because GF and PP2 had no effect on the phosphorylation of ERK
induced by DOTAP.
[0179] To further verify that the ERK pathway is involved in the
CCL2 release initiated by DOTAP, the RNA interference approach was
utilized to block the ERK gene expression in BMDC. FIG. 20A
indicated that the ERK1 was down-regulated by specific siRNA after
24 h treatment. DOTAP--induced CCL2 release was also attenuated in
the cells treated with siRNA, which blocked ERK1 gene expression
(FIG. 20B). However, even though ERK1 was down-regulated, LPS
continued to induce CCL2 release (FIG. 20B). The data also
demonstrate that ERK1 siRNA treatment did not affect other
signaling pathways.
[0180] So far, the data demonstrate DOTAP--induced ERK activation
and down-stream induction of CCL2 in vitro. We have investigated if
the above signaling mechanism plays a role in the adjuvant activity
of DOTAP in vitro. DOTAP/E7 liposome vaccine formulation was used
to subcutaneously immunize mice, and the draining lymph nodes were
collected and assayed by ELISA for CCL2. The data show that CCL2
accumulated in the draining lymph nodes after immunization and the
maximum accumulation was 2 days post injection (FIG. 21A). These
data were confirmed by immunohistochemistry staining (FIG. 21B).
The same data also demonstrate that more lymphocytes migrated to
the draining lymph nodes upon DOTAP/E7 treatment, resulting in the
enlargement of the nodes.
[0181] The inhibitors of ERK and p38 pathways were also formulated
in the DOTAP/E7 liposome complexes. DOTAP/E7/U-0126 and
DOTAP/E7/SB203580 formed clear suspensions but PD98059 was
difficult to formulate in the DOTAP/E7 complex. The stable
DOTAP/E7/drug formulations had similar zeta potentials, particle
sizes and antigen loading capacities as the DOTAP/E7 formulation,
indicating that drug incorporation did not significantly alter the
physical characteristics of the vaccine. Mice were subcutaneously
injected with DOTAP/E7/U-0126 and DOTAP/E7/SB203580. Consistent
with the in vitro data, DOTAP/E7 formulation induced accumulation
of CCL2 in the draining lymph nodes and U-0126 and SB-203580
reciprocally regulated CCL2 induction (FIG. 22A). In order to
determine whether ERK and p38 pathways are related to the
anti-tumor activity of DOTAP/E7, we have examined the anti-tumor
activity of DOTAP/E7/drug formulations. As shown in FIG. 22B,
tumor-bearing mice treated with DOTAP/E7 at the lipid dose of 100
nmoles exhibited a strong growth inhibitory effect on growth of
TC-1 tumor. The ERK inhibitor, U-0126, when co-formulated with
DOTAP/E7, at a similar lipid dose completely abolished the
anti-tumor activity of DOTAP/E7. Similarly, partial inhibition of
anti-tumor activity was shown when mice received treatment with
DOTAP/E7 co-formulated with SB203580, indicating both p38 ERK
pathways play important roles in the antitumor activity of the
DOTAP/E7 complex.
[0182] C. DISCUSSION
[0183] Liposomes are closed vesicle structures consisting of
bilayers of hydrated amphipathic lipids [Small D. M., Surface and
bulk interactions of lipids and water with a classification of
biologically active lipids based on these interactions, Federation
Proc. 29:1320-1326, (1970)]. Since they were identified as
adjuvants in 1974 [Allison A. G. and Gregoriadis G., Liposomes as
immunological adjuvants, Nature 252:252, (1974)], liposomes have
been extensively explored as a delivery system for protein and DNA
vaccines [Chen W. C. and Huang L., Non-viral vector as vaccine
carrier, Adv Genet. 54:315-37, (2005); Gregoriadis G., et al.,
Vaccine entrapment in liposomes, Methods 19:156-62, (1999); Perrie
Y., et al., Liposome-mediated DNA immunization via the subcutaneous
route, J Drug Target 11:555-63, (2003)]. Liposomes show several
unique advantages for antigen delivery. Firstly, there is
significant versatility in lipid composition, size, lamellarity,
charge, and methods of preparation, which can be chosen for
specific applications. Furthermore, considering the carrier to
antigen ratio, the liposomal vesicle system has high efficiency of
antigen loading in the form of encapsulation or stable association.
From the safety point of view, liposomes are biodegradable,
biocompatible and have a low immunogenicity [Copland M. J., et al.,
Lipid bases particulate formulations for the delivery of antigen,
Immunol Cell Biol 83:97-105, (2005); O'Hagan D. T. and Singh M.,
Microparticles as vaccine adjuvants and delivery systems, Expert
Rev Vaccines 2:269-83, (2003)]. Furthermore, liposomes have also
been used to introduce protein antigens into the cytosolic MHC
class I pathway to generate CD8.sup.+ T cell responses [Chikh G.
and Schutze-Redelmeier M. P., Liposomal delivery of CTL epitopes to
dendritic cells, Biosci Rep 22:339-53, (2002)].
[0184] Since cationic liposomes can interact with the negatively
charged cell membrane, they are widely used for gene therapy and
vaccine delivery [Anderson P., Effective vaccination of mice
against Mycobacterium tuberculosis infection with a soluble mixture
of secreted mycobacterial proteins, Infect Immun 62:2536-44,
(1994); Hasegawa A., et al., Nasal immunization with diphtheria
toxoid conjugated-CD52 core peptide induced specific antibody
production in genital tract offemale mice, Am J Reprod Immunol
34:305-11, (2002)]. However, the cationic liposomes themselves have
been regarded as being inert in terms of being able to activate
innate immune responses [Moinegeon P. et al., Towards the rational
design of Thladjuvants, Vaccine 19:4363-72, (2001)]. However,
cationic liposomes can also induce expression of the co-stimulatory
molecules CD80 and CD83 and activate human dendritic cells (FIGS.
23A-E and 25A-B). They also induce human dendritic cells to produce
critical chemokines and cytokines involved with generating a potent
immune response to disease (FIG. 24A-F). These findings all suggest
that cationic liposomes in addition to effective delivery to the
dendritic cells are potent activators of the immune system.
[0185] Unlike the currently used adjuvants such as Alum, CpG, and
CFA, the cationic lipid immunomodulators do not enhance the
expression of NF-.kappa.B, demonstrating that immune system
stimulation by cationic lipids is signaled through an NF-.kappa.B
independent mechanism, eliminating the probability of LPS-like
inflammatory responses from our cationic lipid based therapies.
These studies indicate that cationic liposomes, in addition to
being an efficient delivery system, belong to a unique class of
immune stimulants with an improved safety profile.
[0186] In this specification, the possible molecular mechanisms of
the adjuvant activity of cationic liposomes were studied. Various
components of the MAP Kinase signaling pathway were investigated
for their role in the immunostimulatory activity of the cationic
lipids. The lipids were investigated as an active stimulator of
dendritic cells. It was demonstrated that chemokine production was
induced by the cationic lipids and the induction was mainly
mediated by the ERK pathway. Moreover, the data clearly show that
the p38 pathway negatively regulates this process. A recent report
demonstrated that p38 plays a negative role in IL-2 production,
mainly mediated through its ability to regulate the activity of
ERK. A p38-specific inhibitor induced ERK activation, ultimately
leading to increased IL-2 gene activation [Kogkopoulou 0., et al.,
Conditional up-regulation of IL-2 production by p38 MAPK
inactivation is mediated by increased Erk1/2 activity, J Leukoc
Biol 79:1052-60, (2006)]. Phosphorylation and activation of p38
enhances its interaction with ERK1/2 and correlates with the
inhibition of ERK1/2 phosphotransferase activity, suggesting that
activated p38 may sequester ERK1/2 and sterically block their
phosphorylation by MEK1 [Zhang H., et al., Stress-reduced
inhibition of ERK1/2and ERK2 by direct interaction with p38MAP
kinase, J Biol Chem 276:6905-8, (2001)]. Recent work suggests that
the robust and sustained phosphorylation of ERK results in
phosphorylation of the AP-1 transcription factor c-Fos in dendritic
cells, which in turn suppresses expression of the T.sub.h1-defining
cytokine IL-12, thus favoring T.sub.h2 bias. However, our results
show two significant differences to those reports. First, the
Pam-3-cys (a TLR-2 ligand) utilized in those studies showed enhance
ERK activation compared to LPS (Dillon et al., 2004) but the
cationic lipid-induced ERK activation is less than that observed by
LPS. We also examined IL-10, a T.sub.h2 cytokine, and the results
showed no induction of IL-10 by DOTAP (data not shown). Therefore,
the signal of ERK induced by DOTAP is not enough to trigger the
T.sub.h2 response. Second, DOTAP-induced down-regulation of the
IL-1 signal could also suppress the Th2 response. It appears that
the DOTAP-induced ERK activation is properly controlled.
[0187] Our results suggest that PI-3 kinase is required for
DOTAP-induced activation of ERK and induction of CCL2. Further
investigation is necessary to identify the precise connection
between PI-3 kinase and ERK. Although ELISA data show that PTx
inhibits CCL2 release induced by DOTAP, DOTAP-induced ERK
phosphorylation is only slightly inhibited by PTx as shown with the
Western blot data. Therefore, G protein coupled receptors may or
may not be involved in the signal transduction initiated by DOTAP.
Interestingly, lysophosphatidycholine (LPC) induces G2A
receptor-dependent ERK activation and T cell migration [Radu C. G.,
et al., T cell chemotaxis to lysophosphatidylcholine through the
G2A receptor, Proc Natl Acad Sci USA 101:245-50, (2004)]. The
authors originally reported that LPC was a ligand of G2A receptor
[Kabarowski J. H., et al., Lysophosphatidylcholine as a ligand for
the immunoregulatory receptor G2A, Science 293:702-5, (2001)], but
subsequently, LPC-induced ERK activation was demonstrated through
the mechanism of regulating intracellular sequestration and surface
expression of G2A receptors [Wang L, et al.,
Lysophosphatidylcholine-induced surface redistribution regulates
signaling of the murine G protein-coupled receptor G2A, Mol Biol
Cell 16:2234-47, (2005)]. The active cationic lipids contain a
large polar head group and two long acyl chains. Such structural
characteristics may facilitate their insertion into the lipid
membranes, resulting in the possible alteration of spontaneous
curvature of the lipid monolayer, as well as the conformational and
functional changes of membrane proteins.
[0188] Since p38 negatively regulates ERK activation of CCL2
induction, we expected the p38 inhibitor, SB203580, formulated in
DOTAP/E7 vaccine could enhance the anti-tumor activity. However, an
opposite result was found implying that p38 may also play a
positive role in the D0TAP/E7-induced tumor regression. Since
cationic liposomes can induce the generation of reactive oxygen
species (ROS), which can lead to p38 activation, it is possible
that DOTAP induced p38 activation is through ROS (Iwaoka et al.,
2006). Accumulated evidence shows that p38 activation induces Thl
cytokine release from dendritic cells [DeSilva D. R., et al., The
p38 mitogen-activated protein kinase pathway in activated and
Anergic Th1 cells, Cell Immunol 180:116-23, (1997); Yu J. J., et
al., Regulation and phenotype of an innate Th1 cell: role of
cytokines and the p38 kinase pathway, J Immunol 171:6112-8,
(2003)]. In mammalian species, MAP kinases (ERK, p38 and JNK) are
involved in all aspects of the immune response, from the initiation
phase of innate immunity, to the activation of the adaptive
immunity, and to cell death when immune function is complete [Dong
C., et al., MAP kinases in the immune response, Annu Rev Immunol
20:55-72, (2002)].
[0189] A great variety of experimental adjuvants are available for
use in animals and some of them have been tested in clinical
trials. They include several water-in-oil emulsions, liposomes, and
other chemical adjuvants [Vogel, F. R., and Powell, M. F.A
compendium of vaccine adjuvants and excipients. Pharm Biotechnol
6:141 (1995)]. However, only influenza virosomes [Gluck, R., and
Walti, E., Biophysical validation of Epaxal Berna, a hepatitis A
vaccine adjuvanted with immunopotentiating reconstituted influenza
virosomes (IRIV). Dev Biol (Basel) 103:189 (2000)] and Chiron's
MF59 [Kahn, J. O., et al., Clinical and immunologic responses to
human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine
combined with MF59adjuvanl with or without muramyl tripeptide
dipalmitoyl phosphatidylethanolamine in non-HIV-infected human
volunteers. J Infect Dis 170:1288 (1994)] are already launched on
the market in addition to the aluminum salts. Similar to cationic
liposome (unpublished data), the submicron emulsion based adjuvant,
MF59, is internalized by dendritic cells [Dupuis, M., et al.,
Dendritic cells internalize vaccine adjuvant after intramuscular
injection. Cell Immunol 186:18 (1998)]. It stimulates a variety of
immune activities that lead to high antibody and T-cell reactions
against co-delivered antigens. However, according to the clinical
trial report on HSV and influenza vaccines [Jones, C. A., and
Cunningham, A. L., Vaccination strategies to prevent genital herpes
and neonatal herpes simplex virus (HSV) disease. Herpes 11:12
(2004); and Minutello, M., et al., Safety and immunogenicity of an
inactivated subunit influenza virus vaccine combined with MF59
adjuvant emulsion in elderly subjects, immunized for three
consecutive influenza seasons. Vaccine 17:99 (1999)], evidence from
animal models suggests that the MF59 adjuvant enhances neutralizing
antibodies rather than T-cell responses. Therefore, cationic
liposomes as a vaccine adjuvant is different from MF59 in that it
generates a strong cell-mediated immune response as shown by our
data.
[0190] The cationic lipid/antigen complex appears to be the
simplest cancer vaccine formulation ever reported. It only contains
two molecules, i.e. an antigen and a carrier. In addition to the
delivery of the E7 peptide to the cytoplasm of the antigen
presenting cells such as, for example, the dendritic cells, DOTAP
must also activate DC. Indeed, liposomes consisting of DOTAP alone
induce the expression of CD80/CD86 co-stimulatory molecules in
dendritic cells.
[0191] In conclusion, our findings suggest for the first time that
cationic liposomes are potent immune system stimulators. The
results reported herein shed light on the molecular mechanisms of
the adjuvant activity of cationic lipids such as, for example,
DOTAP.
[0192] DOTAP mediates the induction of several chemokines and
cytokines whose expression is mediated by the ERK pathway. Our
studies also identified the ERK pathway as a new molecular marker
for the evaluation of the adjuvant activity of cationic liposomes.
These markers may be used for high-throughput screening or design
of potent lipid based adjuvants and vaccine delivery systems,
Example 3
[0193] Demonstration of the Immunostimulatory Capability of
Cationic Lipid/Antigen Complexes in Cells of the Human Immune
System
[0194] 1. Cationic lipid/E7 complexes activate human dendritic
cells in a lipid dose dependent manner
[0195] Cationic liposomes were prepared as described above. The E7
antigen used in the formulation is the identified human E7 peptide
restricted by HLA-A*0201 (HPV-16 E7, amino acids 11-20, YMLDLQPETT
(SEQ. ID. NO. 2). The peptide was synthesized by the University of
Pittsburgh, Molecular Medicine Institute, Pittsburgh, Pa. Human
HLA-A2 human dendritic cells were obtained from Lonza (of
Walkersville, Md.). Frozen cryovials were thawed and the dendritic
cells were cultured in LGM-3 medium (commercially available from
Lonza of Walkersville, Md.) supplemented with 50 microgram/ml IL-4
and GM-CSF at 37.degree. C. and 5% CO.sub.2 at an initial plating
density of 125,000 cells/cm.sup.2 in 2 ml of medium in 12-well
tissue culture dishes. The cells were grown for 3 days in culture
and appeared as a mixture of adherent and rounded cells by
microscopic examination.
[0196] The cells were treated on day 3 with a fresh dose of 50
microgram/ml of IL-4 and GM-CSF (all wells) and test wells were
treated with either a mixture of interleukin 1-beta ("IL-.beta."),
interleukin 6 ("IL-6") and TNF-.alpha. at 10 ng/ml, and
prostaglandin E2 ("PGE-2") at 10 .mu.g/ml (positive control for
activation), no treatment (negative activation control), and
DOTAP/E7 at 2.5, 10 and 40 micromolar final concentrations, DOEPC
at 2.5, 10 and 40 micromolar final concentrations, and
DOTAP/cholesterol/E7 at 2.5, 10 and 40 micromolar final
concentrations of lipid and cholesterol. Cholesterol, a stabilizer
of the lipid bilayer, was added at 25 mol %. The treated dendritic
cells were maintained in culture for 24 hours and harvested for
cell surface marker staining and flow cytometry analysis. The
harvested cells were counted by hemacytometer and 10 .mu.l of the
following antibody conjugates were added sequentially to each
sample for labeling surface markers: CD8O-FITC, CD83-APC, and
CD86-PE (BD Biosciences). The surface labeled cells were
subsequently analyzed by flow cytometry using a BD FACxcaliber flow
cytometer, and the co-stimulatory dendritic cell marker molecules
CD80, CD83, and CD86 which are produced upon activation, were
monitored. As seen in FIGS. 23A, B, and C primary human dendritic
cells treated with the cationic lipid/E7 complex at various lipid
doses up-regulated the expression of all three co-stimulatory
markers of dendritic cell activation evaluated and required for
successful antigen presentation to T-cells. As seen in FIGS. 23D
and E, additional components such as stabilizers can also be
included in the pharmaceutical compositions without negatively
impacting the immunostimulatory capabilities of the complex.
[0197] 2. Cationic lipid/E7 complexes activate human dendritic
cells and induce chemokine and cytokine production
[0198] Human HLA-A2 dendritic cells (Lonza, Walkersville, Md.),
were treated and grown in culture as described above. On day 3 the
cells were treated with 40 micromolar DOTAP/E7 complex or the
potent immunostimulator lipopolysaccharide (LPS) at 50 micromolar
concentrations (positive control). Medium from assay wells was
removed and centrifuged at 1300 rpm in a microfuge for 5 minutes to
pellet unattached dendritic cells. The supernants were removed and
treated with 10 microliters per ml of Calbiochem (La Jolla, Calif)
protease inhibitor cocktail set I (Cat. No. 539131) and stored
frozen prior to analysis. Samples were analyzed for cytokine
expression by Pierce Biotechnology (Woburn, Mass.) using their
Searchlight Protein Array Multiplex ELISA assay.
[0199] Production of TNF-.alpha. and IL-12 were evaluated, and
production of selected chemokines known to be essential in the
cellular immune response, CCL3, CCL4, CCL5, and CCL19 were all
evaluated (FIG. 24A-F). FIGS. 24 A-F illustrate that the DOTAP/E7
complex induces cytokine and chemokine production by human
dendritic cells. FIGS. 24A-F illustrates DOTAP/E7 induced
production of TNF-.alpha., IL-12, CCL3, CCL4, CC15, and CCL-19
respectively.
[0200] Similarly to the observations made with the murine dendritic
cells (Example 1), unlike LPS, the DOTAP/E7 complex did not induce
significant production of the pro-inflammatory cytokine
TNF-.alpha., confirming that in the human system also NF-.kappa.B
mediated signaling is not activated by the cationic lipids.
DOTAP/E7 stimulates effective production of multiple chemokines
demonstrating that the cationic lipids act as potent immune
stimulators, and provide similar correlates of efficient activation
in both murine and human immune cells.
[0201] 3. Effect of DOTAP/E7 particle size on the activation of
human dendritic cells
[0202] Human HLA-A2 dendritic cells (Lonza, Walkersville, Md.),
were treated and grown in culture as described above. On day 3 the
test wells were treated with either a mixture of IL-.beta., IL-6
and TNF-.alpha. at 10 ng/ml, and PGE-2 at 10 .mu.g/ml (positive
control for activation), no treatment (negative activation
control), the potent immunostimulator lipopolysaccharide (LPS) at
50 micromolar concentrations (second positive control), or 10
micromolar DOTAP/E7 complex with particles sizes 100 nm, 200 nm and
400 nm. The results shown in FIGS. 25A-B demonstrate that the
cationic lipid/antigen complexes can be utilized within a broad
size range to induce an immune response in the development of
immunotherapies.
[0203] Discussion
[0204] Studies described in Examples 1 and 2 led to the development
of an immunotherapy formulation consisting of a cationic
lipid/antigen complex. Upon stimulation with cationic lipids such
as DOTAP and DOEPC, murine bone marrow derived dendritic cells
(BMDC) were activated for the expression of the co-stimulatory
molecules, CD80 and CD86 [Vangesseri et al, Immunostimulation of
dendritic cells by cationic liposomes. Mol Membr Biol 23:385-395
(2006)]. The activation of various components of the MAP kinase
signaling pathway and several chemokines such as CCL2 were also
observed in DOTAP-activated BMDC. Animal studies suggested that
DOTAP liposomes within specific dose ranges acts as both an antigen
carrier and a potent adjuvant for inducing migration of the
activated dendritic cells to the draining lymph node, thereby
leading to the generation of in vivo antigen-specific CD8.sup.+ T
lymphocyte against antigen-bearing cells such as tumor cells. In
vitro testing in activation of primary human dendritic cells
indicate that the cationic lipids are potent immunostimulators,
promoting dendritic cell activation toward expression of
co-stimulatory molecules which are required for T-cell recognition
and antigen presentation. We have also demonstrated that human
dendritic cells, upon activation by DOTAP/E7 liposomes, promote
significant proliferation of human T-cells in vitro.
[0205] The studies reported above identify specific unique
compositions and applications of cationic liposomes, which can be
exploited to develop simple, cost effective, and much needed
immunotherapies for several debilitating diseases.
[0206] As various changes could be made in the above-described
aspects and exemplary embodiments without departing from the scope
of the invention, it is intended that all matter contained in the
above description shall be interpreted as illustrative and not in a
limiting sense. To that end, while the examples primarily discuss
the cationic lipids DOTAP, DOEPC, and DOTMA, those skilled in the
art will recognize that these cationic lipids are merely exemplary
and that the methods are applicable to other cationic lipids.
[0207] In compliance with 37 C.F.R. .sctn. 1.821(f), the applicants
submit that the sequence listing information recorded in computer
readable form is identical to the written sequence listing.
Sequence CWU 1
1
1019PRTAlphapapillomavirus 9 1Arg Ala His Tyr Asn Ile Val Thr Phe1
5210PRTAlphapapillomavirus 9 2Tyr Met Leu Asp Leu Gln Pro Glu Thr
Thr1 5 10320DNAArtificial SequenceDescription of Artificial
Sequence Synthetic primer 3aagccagctc tctcttcctc 20421DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
4cctctctctt tgagcttggt g 21520DNAArtificial SequenceDescription of
Artificial Sequence Synthetic primer 5atcatgaagg tctccaccac
20620DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 6tctcaggcat tcagttccag 20720DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
7gctctgtgca aacctaaccc 20822DNAArtificial SequenceDescription of
Artificial Sequence Synthetic primer 8tgtgatggtg ggaatgggtc ag
22922DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 9tttgatgtca cgcacgattt cc 221024DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
10tttttttttt tttttttttt tttt 24
* * * * *